Annual Report 2024-25
Charity report and financials for Mesothelioma UK for period ending 31 March 2025.
Mesothelioma UK Registered Charity Number: 1177039
Registered Address:
235 Loughborough Road, Mountsorrel, Loughborough, Leicestershire, LE12 7AS
Mesothelioma UK
Contents
| Contents | |
|---|---|
| Foreword from the CEO | 1 |
| Objectives & Activities | 2 |
| How We Work | 3 |
| 1. Improving Outcomes & Experiences | 4 |
| 2. Research | 16 |
| 3. Information | 19 |
| 4. Awareness | 21 |
| 5. Sustainability & Fundraising | 23 |
| Trustees Report | 37 |
| Looking Forward | 40 |
Annual Report 2025
Foreword from the CEO
Thank you and congratulations to the whole Mesothelioma UK team - our nurses, board of trustees, operational team, volunteers, ambassadors, our corporate and charity partners, and to everyone that has fundraised or donated to the charity. This is your charity and what you have achieved together, as you will see in this report, is exceptional.
Behind the scenes, the restructured operational team have been busy reorganising and team building. They are stronger than ever, with a more suitable structure and a clear vision that is outlined in the charity’s new strategy that was published earlier this year.
The charity works closely with patients and their families to identify their needs and prioritises activities and services to meet them. The strength of our engagement has led to new courses for patients and carers and has influenced our research activities, with studies focused on peritoneal mesothelioma and the role of the coroner.
This last year, Mesothelioma UK has contributed significantly to awareness and prevention. People affected by mesothelioma often ask us to do all that we can to prevent others being exposed and put at risk. Through our research, reports, and communication, the charity has been able to give voice to people and share stories and experiences that have added invaluable clarity and truth to the UK’s ongoing discussions and debate about asbestos.
To strengthen our awareness and prevention efforts, the charity has been partnering with companies across the UK involved in asbestos management. The benefits of collaboration are clear, as we work together to reduce the harmful impact of the UK’s dreadful asbestos legacy.
The reputation of our nursing team grows year on year. They have been described as a ‘tour de force’. Their contribution to the NHS, to mesothelioma treatment and care, and to the individual patients they support is appreciated and
acknowledged beyond the UK. This last year, the nursing team have responded to requests from South Africa, Japan, Cambodia, The Netherlands and Australia to network and share – attending educational events, and hosting visits and placements. Wherever our nurses go, and with whomever they connect, they carry with them our patients – their stories, their voices and their experiences. We are tremendously grateful to everyone who so generously and openly shares their story, allowing others to learn and find strength through their experiences.
It is tragic and shameful that the UK has such a dreadful asbestos legacy, but the Mesothelioma UK community is a shining example of our nation at its best; people pulling together and doing all that they can to help others and improve a seemingly impossible situation.
Thank you to each and every one of you that willingly works with and supports the community. The difference you make, detailed over the next few pages, is so appreciated.
Thank you.
Liz Darlison
CEO, Mesothelioma UK
1
Mesothelioma UK
Objectives & Activities
We are a national charity dedicated to supporting people affected by mesothelioma through expert care, information, and advocacy.
Our mission is twofold: to improve the lives of those living with the disease today and to help prevent future cases. We do this by championing equitable access to care, advancing research, and ensuring the voices of those with mesothelioma are heard.
Founded in 2004 as a Macmillan Cancer Support Resource Centre at University Hospitals of Leicester, Mesothelioma UK has grown from humble beginnings into a nationally recognised charity. We became
an independent organisation in 2008, and in 2018 registered as a Charitable Incorporated Organisation. By 2020, our charitable activity exceeded £1 million – a significant milestone in our development.
Since our inception, our core focus has been providing access to Mesothelioma Clinical Nurse Specialists (CNSs) where they are needed most – at the heart of the NHS and in hospitals across the UK. These specialist nurses offer invaluable support, delivering expert care, increasing access to clinical trials, expanding treatment options,
reducing emergency admissions, improving symptom management, and ultimately enhancing patients’ quality of life.
We also recognise that many individuals diagnosed with mesothelioma are passionate about preventing future cases. That’s why we collaborate with partner organisations to raise awareness about asbestos and highlight the devastating impact of mesothelioma nationwide.
2
Annual Report 2025
~~How We~~ How We Work Work Five key pillars represent the scope and aims of the charity: Improving Outcomes & Experiences, Research, Information, Awareness, and Sustainability & Fundraising. Our strategy gives more details on how we work. We use these pillars as a way to showcase our key activities and achievements throughout this report. w
3
Mesothelioma UK
1. Improving Outcomes & Experiences
Our Nurse Team
Our mesothelioma nurses play a vital role in the care of people diagnosed with mesothelioma, providing expert holistic care and guidance through diagnosis, complex treatment pathways and symptom management.
This past year has continued to be challenging for all those working in the NHS, as healthcare teams continue to recover from the effects of the pandemic, meeting growing demand for services, and ongoing staff pressures. Despite all of this, our specialist mesothelioma nurses have continued to deliver outstanding care. Their dedication, compassion, and determination to support patients and families remain truly inspiring. They consistently go above and beyond to ensure people affected by mesothelioma receive the expert support they need.
As a charity, we know how tough the economic climate has been. This year we have focussed on sustainability and development of the team and every single one of our nurses continues to build their skills and knowledge, helping to make sure we deliver the highest standards of mesothelioma care across the UK.
Our nurses have continued to showcase their work and educate others at a variety of esteemed conferences - including the British Thoracic Oncology Group and Lung Cancer Nursing UK. They have also worked alongside Lung Cancer Nursing UK to develop an online educational resource for lung cancer nurses. The nurses have continued to lead and support local events, raise
awareness, and play a key role in fundraising and support group activities across the country – especially on Action Mesothelioma Day.
We remain focused on reaching people affected by mesothelioma in all parts of the UK. In Scotland, our nurses are at the heart of the Scottish Mesothelioma Network, helping to provide coordinated care through a national clinical team. In Wales, we have been working to ensure people diagnosed with mesothelioma and their families continue to have access to a dedicated mesothelioma nurse. We have continued to develop strong partnerships with clinical teams in Northern Ireland and Macmillan which led to the country’s first mesothelioma nurse posts being established in September.
We launched our new Mesothelioma UK Nursing Network with the aim of sharing knowledge, supporting one another, and driving improvements in care. In January we shared the first edition of Mesothelioma in Focus , our newsletter written specifically for healthcare professionals to keep them up to date on the latest developments in mesothelioma treatment and care.
As we look to the year ahead our nurses are preparing to present their work at the biannual International Mesothelioma Interest Group Conference (iMig) which will be held in Philadelphia, USA in October 2025. The Mesothelioma UK nurse specialist model is internationally recognised as best practice in mesothelioma nursing.
Finally, I want to say a huge thank you to our nurses – for their energy, compassion, and unwavering commitment to the mesothelioma community. I am proud to support them and look forward to what the next year will bring.
Leah Taylor Head of Nursing
4
Annual Report 2025
Nursing Team Update
Welcoming new faces and fond farewells
Over the past year, we welcomed new nurses to our team and said heartfelt goodbyes to several valued colleagues who have made a lasting impact on our work.
We bid farewell to:
Anne Moylan ,
one of our longest-serving senior nurses, spent ten dedicated years with the charity. Based in Portsmouth, Anne served as a Team Leader and led much of our work with the Armed Forces community. She has now taken on a new challenge, bringing her skills and experience to a lung screening programme.
Becky Weston-Thomas,
based at Aneurin Bevan University Health Board in Wales, joined us after a gap in service following the retirement of our previous Project Lead. Becky ensured that patients continued to receive specialist mesothelioma nursing support. She left the team in November to take up a new role in cancer care.
Sophie Phillips,
our mesothelioma nurse in Birmingham, retired in September after a distinguished and impactful career. Sophie was a key source of support for patients across the West Midlands and is deeply missed by colleagues and the community alike.
Sam Jayasekara,
based at Broomfield Hospital, provided essential support across Essex. A highly experienced nurse specialist, Sam was involved in several key charity projects, including the delivery of our Carers Course. She relocated in December and continues her work within cancer care.
Catherine Stoten
joined the nursing team in March 2023 as the first mesothelioma nurse at University College London Hospital. Before moving overseas, Cat played a crucial role in establishing the mesothelioma nursing service there, leaving a solid foundation for her successor.
We thank Anne, Sophie, Catherine, Becky, and Sam for their dedication and compassion. Their contributions have made a significant difference to the lives of those affected by mesothelioma, and we wish them all the very best in their future endeavours.
5
Mesothelioma UK
At the same time, we were pleased to welcome five new nurses to the team, each bringing a wealth of experience and expertise:
Karen Connolly
joined in August, working within the lung cancer team at St Bartholomew’s Hospital in London.
Stephanie Todd and Carol Johnston
were welcomed to the team in September. Stephanie and Carol are based within Belfast Health and Social Care Trust and have joined us as the first mesothelioma nurses in Northern Ireland. Their posts are generously funded by Macmillan Cancer Support for the first three years.
Sonya Moudart
became part of the lung cancer team at University College Hospital London in December.
Lyndsey Haffenden
joined us in January and is based at Cwm Taf University Health Board in Wales. Lyndsey’s post is generously funded by Macmillan Cancer Support for the first two years.
Facts & Figures
Total number of new patients referred to one of our Mesothelioma UK nurses
1,031
Similar numbers reported in last fiscal year
Episodes of care* provided by our Mesothelioma UK nurses for both new and existing mesothelioma patients
- Support and advice on topics including symptoms, pain, treatment options, clinical trials, psychological support
36,961
24% more than in previous fiscal year
Total number of support groups attended*
- Groups held locally or virtually where patients and families can meet our nurses, ask questions, and feel supported
368
Similar numbers reported in last fiscal year
Number of MDT* meetings attended
- Multi-Disciplinary Team – group of healthcare professionals working together to make decisions on the best course of care for patients
929
Similar numbers reported in last fiscal year
We are incredibly grateful to our partners, many of whom have generously funded key nursing posts and continue to be a vital source of support for our entire team. Their commitment, along with the efforts of their donors and fundraisers, makes it possible for us to make a meaningful and lasting impact on the lives of people affected by mesothelioma across the UK.
Annual Report 202 45
Nurse Case Study
Recognised for her expertise nationally and internationally, Sam regularly shares her knowledge on prominent platforms.
Samantha Westbrook
The first Peritoneal Mesothelioma Clinical Nurse Specialist in the UK
Since her appointment in 2018, Samantha Westbrook has been a pioneering force in the care of people affected by peritoneal mesothelioma – the UK’s first nurse specialist dedicated exclusively to this role.
Based at the Peritoneal Malignancy Institute within Basingstoke and North Hampshire NHS Trust, Sam plays a vital role in a large, multidisciplinary team focused on peritoneal disease.
Sam independently manages a national caseload of adults living with peritoneal mesothelioma, working closely with local and regional healthcare teams across the UK to ensure patients receive timely and specialist care. She is a core member of the peritoneal mesothelioma multidisciplinary team (MDT), which meets twice monthly to develop personalised treatment plans that are communicated to local hospital teams.
Beyond clinical duties, Sam is a cornerstone of patient support. She hosts the Mesothelioma UK Facebook group – a closed community for people affected by peritoneal mesothelioma – and facilitates two virtual support groups monthly, a dedicated WhatsApp group, and a unique buddy system. These services connect patients both nationally and internationally, fostering a supportive network. Additionally, Sam co-organises an annual wellbeing event with the Peritoneal Malignancy Institute and HASAG, offering patients the opportunity to learn from specialists and each other.
Sam is active in research, co-leading a study in partnership with the Mesothelioma UK Research Centre at the University of Sheffield, examining patient pathways and care experiences.
Recognised for her expertise nationally and internationally, Sam regularly shares her knowledge on prominent platforms to advance peritoneal mesothelioma treatment and care.
Sam’s role is funded by Mesothelioma UK.
7
Mesothelioma UK
Highlight on Wales
Project Cymru ran for three years until 2023, with the goal of developing a cohesive mesothelioma service across Wales.
Central to this vision was the creation of a hub-and-spoke model, anchored by an all-Wales specialist mesothelioma multidisciplinary team (MDT). While funding for the MDT was approved by the Welsh Health Specialised Services Committee (WHSSC), progress toward establishing the service has been limited.
Following the retirement of our project lead, the charity’s focus shifted to reinstating and sustaining a mesothelioma clinical nurse specialist (CNS) post in Wales, with initial support from Macmillan Cancer Support. A new CNS post was established at the end of 2023; however, the postholder departed after a year, resulting in another gap in provision. In January 2025, a new nursing post was appointed at Cwm Taf University Health Board, and discussions are ongoing regarding a further position at Aneurin Bevan University Health Board to help maintain access to specialist mesothelioma nursing support.
We are sincerely grateful to Macmillan Cancer Support for their funding and commitment, which remains essential to sustaining mesothelioma nursing services across Wales.
8
Annual Report 2024Annual Report 2025
Highlight on Scotland
The Scottish Mesothelioma Network (SMN) was launched in 2019 in partnership with NHS Scotland, Macmillan Cancer Support and Mesothelioma UK.
In 2021 the network successfully secured recurrent funding from the Scottish Government and subsequently moved into the Scottish Cancer Network (SCN). The SCN currently manages, supports and governs five national cancer networks facilitating national integration and collaboration for specific cancers and making best use of expert resources with the aim of improving patient outcomes.
The SMN provides a forum for clinical teams across Scotland to share expertise, speed up diagnosis, develop high quality care plans, provide information and support, maximise equitable access to clinical trials and facilitate optimal care delivery as close to home as possible. The network also ensures patients have access to a local, dedicated Lead Clinician and Mesothelioma UK Clinical Nurse Specialist.
There are five Mesothelioma UK Clinical Nurse Specialists (CNS) across Scotland, one in each of the health board regions:
-
Carolyn MacRae, Mesothelioma UK CNS and Team Lead for Scotland, based at Queen Elizabeth University Hospital, Glasgow
-
Tracy Petrie, Mesothelioma UK CNS, based at Aberdeen Royal Infirmary, Aberdeen
-
Lynne Hunter, Mesothelioma UK CNS, based at Western General Hospital, Edinburgh
-
Jenn Latham, Mesothelioma UK CNS (affiliated post), based at Raigmore Hospital, Inverness
The CNS team are an integral part of the network, possessing specialist knowledge, skills, competencies and experience. They play a key role in the planning and delivery of care and services to meet the unique, complex needs of patients diagnosed with mesothelioma.
The network has built strong links with legal services and charity support organisations to ensure that patients and their families across Scotland are offered the most upto-date advice, as well as holistic emotional and practical support. The network also provides online and in-person education and training to patients and the health care professionals involved in the treatment and care of those affected by the disease.
Quality Performance Indicators (QPIs) measuring outcomes that reflect the quality of care and processes delivered across the network is gathered by the MDT coordinator and audit facilitator. This allows continuous improvements in services and outcomes, including patient survival and quality of life. The initial baseline review of the network’s QPIs took place in 2021 with a further review reflecting three years of data now available.
- Susan Smyth, Mesothelioma UK CNS, based at Ninewells Hospital, Dundee
9
Mesothelioma UK
Information and Support
Website:
The SMN has a dedicated website with information for patients in Scotland on how to access treatment, clinical trials, support groups and other relevant information. This can be accessed by clicking this link: Scottish Mesothelioma Network.
Patient Information:
The network has continued to provide nationally agreed, standardised patient information packs across every health board region to anyone diagnosed with mesothelioma. This pack contains a mesothelioma patient information booklet, local asbestos charity information and contact details, Mesothelioma UK care record, Mesothelioma UK keeping-in-touch card and clinical trials app details, an invitation to the network support group and local Mesothelioma CNS contact details.
Newsletter:
A regular network newsletter has been created to help raise awareness and share all the news and developments in relation to mesothelioma across Scotland and the SMN itself. It is sent to all members of the network and our partner organisations. It is also sent to all the Scottish Lung Cancer CNSs (via the Scottish Lung Cancer CNS Forum) and is available to patients and their families if desired via the network website. The current issue along with a back catalogue can be viewed on the Scottish Mesothelioma Network website.
Highlights from 2024/2025
-
Sustained delivery of high quality clinical care across the country.
-
Improved access to diagnostic procedures, with local anaesthetic thoracoscopy now available in each of the health board region.
-
Multicentre ambispective cohort study evidencing the impact of the network since its launch, suggests improved survival of patients with pleural mesothelioma and evidences the benefit of the expert National MDT Model.
-
Clinical Audit of Mesothelioma Quality Performance Indicators (QPIs) comparison demonstrated improvements in the diagnostic pathway (imaging and histopathology) over the past four years of QPI reporting.
-
National Clinical Management Guidelines for mesothelioma have been developed in collaboration with clinical representatives from all specialities and regions across Scotland.
-
Successful implementation of key performance indicators for the network’s MDT coordinator and audit facilitator roles, evidencing the value of the role in coordinating the patient pathway nationally.
-
Successful in person education event at the Royal College of Physicians in Edinburgh on 6 February was attended by 80 representatives from the mesothelioma community clinical and support services from across the country.
The year ahead
Over the coming year, the network is looking forward to:
Education Events:
The network team continue to host an annual education and networking event for health care professionals and those with a specialist interest in the care of those affected by a diagnosis of mesothelioma.
-
Formal publication of the SMN MDT Impact Evaluation.
-
The final review, consultation and publication of national clinical management guidelines.
-
Launch of our new online Support Group, facilitated by Mesothelioma UK.
-
Development of a Patient Reported Outcome Measures Working Group.
-
Ongoing QPI reporting and production of an Annual Clinical Audit Report.
-
Ongoing weekly national MDT meetings.
-
Ongoing high quality equitable care, information, support, and access to clinical trials for all patients affected by Mesothelioma across Scotland.
10
Annual Report 2024Annual Report 2025
Project Northern Ireland
Reflection on the new regional mesothelioma clinical nurse specialist service
Mesothelioma is a rare and aggressive cancer primarily caused by asbestos exposure. In Northern Ireland, the incidence of mesothelioma reflects the region’s industrial history, particularly its shipbuilding sector.
Approximately 50 people are diagnosed with mesothelioma each year in Northern Ireland. Most cases occur in individuals aged 60-80, with men being more commonly affected than women.
Northern Ireland has been the only region within the United Kingdom without a designated mesothelioma clinical nurse specialist resulting in patients with mesothelioma not having access to the same specialist knowledge, skills and expertise as those in other parts of the UK.
Due to this there has been an aspiration by Mesothelioma UK to align Northern Ireland with England, Scotland and Wales in relation to the provision of a mesothelioma nursing service. This was the vision several years ago of the CEO of Mesothelioma UK, Liz Darlison. However, this service really came to fruition due to the drive and determination of The Rodgers family from Northern Ireland who initially engaged with Mesothelioma UK when a family member was diagnosed.
The family have since worked tirelessly raising funds and awareness alongside Mesothelioma UK for the last few years to establish this specialist nursing role in Northern Ireland.
Fortunately, the vision was also shared by Macmillan who have generously funded the role for the first three years with onward funding by Mesothelioma UK and Belfast Trust. Broken down this is 0.4 whole time equivalent (WTE) funded by Mesothelioma UK and 0.6 WTE via the Belfast Health and Social Care Trust, through agreed commissioned Clinical Nurse Specialist funding.
The post of the regional mesothelioma CNS service commenced 1 September 2024. It is a Band 7 role of 37.5hrs/week with post holders covering 18.75hrs/week each. Both post holders are working their remaining hours as Lung Cancer Clinical Nurse Specialists.
The post is based within the Belfast Health & Social Care Trust (BHSCT) but provides a service for patients with mesothelioma in the Northern, Southern, South Eastern and Western Trusts.
The BHSCT has four hospital sites with three of these sites being the main location where patients with mesothelioma will be admitted or attending as outpatients. The mesothelioma CNS acts as keyworker for these patients within BHSCT and is a conduit for health professionals and patient/relatives with information pertaining to mesothelioma offering advice, support and education province wide.
The initial phase has centred on establishing the service, with a key focus on analysing current mesothelioma diagnosis statistics and patient demographics. This scoping exercise has provided valuable insight into population needs and laid the foundation for shaping the direction and future development of the service.
To date, patients and their families have expressed gratitude for the support provided and the ability to access the Mesothelioma CNS service when queries arise. While no formal patient satisfaction questionnaire has yet been implemented, plans are in place to introduce feedback mechanisms as the service continues to grow and become more established. A Care Opinion QR code has been included on the patient information leaflet to encourage informal feedback.
11
Mesothelioma UK
Real Stories
Living Life Fully: Caroline Lyons’ Legacy
Caroline’s nursing jobs had taken her from army hospitals in Northern Ireland, Germany and Hong Kong, all over the NHS and in international primary healthcare schools in rural communities.
After pursuing their careers, husband and wife, Darren and Caroline Lyons moved to their dream destination of Cornwall. They renovated an old house and planned to retire there.
However, after a period of illness in 2020, Caroline was sadly diagnosed with mesothelioma. Although Caroline tragically passed away from the disease in October after a 20 month battle, her legacy now lives on through Darren and daughter, Anna.
A time of real highs and lows
Darren says: “Following an accident where Caroline broke her leg, she then developed a pain in her shoulder
blade, which physio didn’t help. By Christmas 2020, she contracted the flu or a chest infection which prescribed antibiotics didn’t clear. Following an X-ray and a CT scan, she was diagnosed with mesothelioma. It was a massive shock and on Christmas Eve, our daughter announced her pregnancy, so it was a time of real highs and lows.”
Support from nursing teams
Darren continues: “The treatment and care that Caroline received was brilliant. She was referred to the mesothelioma team in Truro and we also made connection with the palliative care team.”
“In July, we visited Anna, Anthony and baby Poppy who live in Glasgow, but Caroline’s health worsened and we could not return to Cornwall. Desperate to survive to see Poppy’s first birthday, Caroline was reluctant to engage with symptom management and end-of-life planning. But only days after Poppy’s birthday in September 2022, Caroline deteriorated, eventually being admitted into the local hospice and passed away just 30 hours later.”
Progressing with civil claim
“We were encouraged to pursue a civil claim and engaged Hugh James solicitors who went through Caroline’s work history. She’d had low level exposure in hospitals and worked in couple of hospitals that had been built with asbestos during wartime but were demolished in the 1990s,” says Darren.
“After a 3-4 year investigation, Hugh James are now putting court papers in so although it can be a long process, Caroline wanted to highlight the dangers of asbestos exposure and bring it to the attention of employers. Irrespective of its success, making a claim does hold those responsible for our welfare to account.”
Changes all round
Darren reflects: “In tribute to Caroline, Anna and I are determined to live our best lives, without fear, doubt or compromise. I think Caroline would agree!”
12
Annual Report 2025
Benefits
Advisors
Access to timely, expert benefits and compensation advice continues to be essential for people diagnosed with mesothelioma. At Mesothelioma UK, we remain committed to ensuring that patients and their families receive the support they need, regardless of location or financial background.
We have built on our existing provision in North East England, led by our Benefits Manager Sarah Thomas, and expanded our reach significantly this year following the successful application for funding from B&CE. This has allowed us to recruit two new Benefits Advisors, Angela Kingston-Nash and Claire Reeves, who are now actively supporting patients in the Bristol and Avon area, as well as responding to national and international enquiries through the Mesothelioma UK Support Line.
To ensure continuity and quality of service, the new advisors underwent an in-depth induction which included training on the complex entitlements available to mesothelioma patients and internal case management systems. They are now fully integrated into our operations team and building relationships with the asbestos community in the Bristol and Avon area.
Their recruitment has strengthened our national coverage and significantly increased our capacity to provide personalised, specialist advice to patients and their families.
We continue to collaborate closely with members of the Asbestos Victims Support Group Forum across the UK, ensuring that patients who contact us can be referred to trusted local specialists where appropriate. We also maintain strong links with healthcare professionals and regularly contribute to training and educational events within the mesothelioma clinical community to raise awareness of the financial support available.
DWP processing delays and campaigning
One of the major challenges remains the delays in processing Industrial Injuries Disablement Benefit and government lump sum payments.
Despite ongoing advocacy and media efforts by Mesothelioma UK, many patients continue to face distressing delays, with some not surviving long enough to receive their entitlements.
In response to growing concern, we met with Sir Stephen Timms MP, Minister of State for Social Security and Disability within the Department for Work and Pensions (DWP) to raise these issues directly. We were reassured that steps are being taken within the DWP to improve processing times. Early statistics suggest a modest improvement, but the pace of change remains slow. We will continue to campaign robustly for urgent reform to ensure patients are not left waiting in their time of greatest need.
Facts & Figures 2024-25
Total number of clients
105
Lump sum payments identified
£1,475,749
Estimated annualised benefits
£1,154,538
Vets UK lump sum
£420,000
13
Mesothelioma UK
Annual Report 2024
Support Line
The Mesothelioma UK Support Line sits at the centre of the support services provided by the charity. A freephone number (Mon-Thurs 9am-4pm, Fri 9am-3pm) provides access to expert support and advice for those not able to find this locally.
In 2023/2024 the Mesothelioma UK Support Line dealt with 359 contacts for support across the three media currently available.
----- Start of picture text -----
210
119
30
----- End of picture text -----
CONTACTS
The medium by which people choose to contact us remains constant with two out of every three people choosing to pick up the phone and speak to us
Via telephone Via email Via website
----- Start of picture text -----
87
56
216
----- End of picture text -----
WHO CONTACTS US FOR SUPPORT AND ADVICE?
There has been a slight year on year increase in the percentage of those contacting us being patients themselves. The bigger percentage remains constant year on year, with contacts from relatives and carers making up two thirds of our overall contact numbers.
Patients Relatives/Carers Other (eg. healthcare professional, well but worried, patient travel)
Calls from those who are well but worried about exposure, averages out at 9% of our calls over the fiscal year 2024/25 but it is worth noting that the second half of the year saw these types of calls increase significantly. We believe this to be a direct consequence of increased media coverage in newspapers and on TV about the dangers asbestos still poses in the UK.
14
Annual Report 2025
Support Line
----- Start of picture text -----
84
60 58
6
13 31 55
52
----- End of picture text -----
CONTACT ENQUIRY TYPES
Compensation and benefits Symptom and pain management New diagnosis Treatment options Well but worried about exposure Clinical trials information Patient travel Other (general enquiries)
Most contacts are about compensation and benefits, symptom and pain management, and new diagnosis and treatment options. This shows a continuing need for our support services for those who are not receiving this information and advice locally.
The Support Line Quality Group continue to meet regularly to monitor these contacts for timeliness and quality of response as well as identifying any gaps in knowledge and training needs within our team. This ensures that our Support Line Service is the best it can be for our patients, their loved ones, our Nursing Team and Mesothelioma UK as a charity.
15
Mesothelioma UK
2. Research
Introduction
Mesothelioma UK aims to support high quality mesothelioma research in the UK, focusing on prevention, new treatments and quality of life. Our goal is to fund pioneering research, promote equitable access to clinical trials and advocate for a National Mesothelioma Audit.
We continue to be proud members of the Association of Medical Research Charities, whose support and guidance we deeply appreciate. We remain steadfast in our commitment to our research objectives. We are immensely grateful to our Research Advisory Steering Committee for their commitment, ensuring that when funding becomes available, we will continue to support only the highest quality research.
----- Start of picture text -----
National
Mesothelioma Audit
National Mesothelioma
Audit report 2020
(for the audit period 2016–18)
Published May 2020
----- End of picture text -----
----- Start of picture text -----
National
Mesothelioma Audit
National Mesothelioma
Audit report 2020
(for the audit period 2016–18)
Published May 2020
----- End of picture text -----
National Mesothelioma audit
Mesothelioma UK remains firmly committed to reinstating the National Mesothelioma Audit – a vital project that, due to funding constraints, has not been undertaken since 2018. This audit, published in 2020 highlighted that, while improvements had been made in some areas such as survival, pathologic sub typing and clinical nurse specialist assessment, variation in active treatments and outcomes existed at cancer alliance and organisational level across the UK. A national audit of this scale provides essential insights into diagnosis, treatment, and patient care, helping us understand who is affected by mesothelioma and how services can be improved.
The findings are crucial in driving equity of access, improving treatment pathways, and informing evidencebased care across the UK. We will be exploring all available options with key stakeholders and partners to ensure that, once reinstated, the audit can be sustainably embedded for the future.
Our aim is to establish a long-term model that prevents future gaps in this vital national data. Re-establishing the National Mesothelioma Audit will be a key priority in our new 2025-2028 strategy, reflecting our ongoing commitment to improving outcomes and quality of life for everyone affected by mesothelioma across the UK.
16
Annual Report 2025
Active Grants
Leveraging clonal genomics to augment diagnostic accuracy and forecast survival in mesothelioma
The aim of this study is to examine the feasibility of a randomised trial of exercise therapy in mesothelioma. The EXTRA-Meso study represents an opportunity to address the unmet need for patients with mesothelioma to improve their wellbeing, physical and functional fitness and health-related quality of life.
Completed Grant 2024-25
Leveraging a new class of cancer target for the benefit of mesothelioma diagnosis and treatment
This was a small, initial grant for six months. Research has shown that MDIG (Mineral Dust Induced Gene),
a gene that has been identified as playing a role in the development and progression of certain cancers, could be a useful target for new mesothelioma treatments. In the short term, this means we should do more studies on how MDIG works in mesothelioma cells and develop drugs to block it. In the long term, it supports further studies to test these drugs and combination therapies, which could lead to better treatments for patients. This grant has helped confirm the initial idea and gather data to apply for larger grants in the future.
17
Mesothelioma UK
Update from the Mesothelioma UK Research Centre
The Mesothelioma UK Research Centre at the University of Sheffield was established in 2020 and is funded by Mesothelioma UK in addition to other national charities and funding organisations.
The end of June 2025 marked an incredible five years for the Research Centre. The team have conducted a programme of research to benefit the care of people diagnosed with mesothelioma and their families and since 2020 have successfully completed over 20 research studies. In 2024/5 the Research Centre completed studies on the role of the coroner/procurator fiscal in mesothelioma and the support needs of family carers in mesothelioma. A nested study within the HIT-MESO clinical trial is also ongoing, which will explore patient experiences of receiving proton beam radiotherapy treatment. In Oct 2024, the team were delighted to welcome a new PhD student (Caitlin Lusted), who will be conducting research into ‘scanxiety’ and the experiences of undergoing scans for mesothelioma. These studies complement our existing portfolio of projects, which all respond to top priorities for mesothelioma research, as identified in our 2021 Research Prioritisation Exercise.
Since the Research Centre was established, the team have achieved the following:
-
Published over 200 research outputs.
-
Published 31 papers in peer review journals (eg. Journal of Advanced Nursing, Palliative Medicine, European Journal of Oncology Nursing).
-
91 posters and oral presentations presented at conferences including iMIG, BTOG, ITONF, LCNUK, IASLC.
-
47 invited presentations contributed at professional events eg. law firms, ASG’s, asbestos monitoring industry seminars.
-
Submitted 25 policy/parliamentary contributions.
-
Contributed to 104 public engagement events including creating animations and films, infographics and events at the Festival of the Mind and Festival of Social Sciences.
-
Developed and premiered the play ‘Invisible Threads’ highlighting issues around asbestos and mesothelioma.
-
Website has had over 20,000 views since it was launched.
-
In September 2025, our book ‘Living with Mesothelioma’ will be published by Routledge.
Our website has had over 20,000 views since it was launched and provides details of all research outputs and studies. We have a dedicated ‘Resources’ webpage which is a repository of professional resources, and a ‘Patient and Public Involvement (PPI)’ webpage which provides details of PPI opportunities.
The Research Centre has also been working hard to support other early career mesothelioma researchers and have provided mentoring and advice to students, nurses, doctors and other aspiring academics.
The Research Centre is led by Prof Angela Tod and Prof Clare Gardiner who work with a team of researchers and PhD students, supported by a Patient and Public Involvement (PPI) panel.
More information about the Mesothelioma UK Research Centre can be found on their website: www.sheffeld.ac.uk/murc.
18
Annual Report 2025
3. Information
At Mesothelioma UK, we are committed to empowering patients and families with timely, accurate, and accessible information.
Our leaflets and booklets are designed to support everyone affected by mesothelioma – whether newly diagnosed, undergoing treatment, or seeking practical guidance. These resources are available to download and are written in clear, compassionate language to help individuals make informed decisions about their care.
We are proud to hold the PIF TICK accreditation, the UK’s trusted quality mark for health information, awarded by the Patient Information Forum. This recognition reflects our dedication to
producing evidence-based, user-tested materials that meet rigorous standards of clarity, relevance, and accessibility.
Our information covers a wide range of topics – from understanding mesothelioma and treatment options to managing symptoms and accessing support services. By continually reviewing and updating our materials,
we ensure they remain responsive to the evolving needs of the mesothelioma community.
----- Start of picture text -----
Immunotherapy Ascites
www.mesothelioma.uk.com www.mesothelioma.uk.com
0800 169 2409 0800 169 2409
----- End of picture text -----
19
Mesothelioma UK
Our Communications
Mesothelioma Matters:
Keeping the mesothelioma community informed and connected
Our bi-monthly e-bulletin, Mesothelioma Matters, reaches patients, carers, and supporters with updates that matter most. Each edition features real-life stories, news from the charity, updates on mesothelioma research and clinical trials and more. With 1,780 subscribers, Mesothelioma Matters plays a key role in keeping our community informed, engaged, and supported.
Social media
We use our social media channels – Facebook, Instagram, X (formerly Twitter), and LinkedIn – to share timely updates on advocacy, research, clinical trials, and charity news. We also spotlight personal stories from across the mesothelioma community, helping raise awareness and build connection.
www.facebook.com/therealmesouk
@mesotheliomauk
https://uk.linkedin.com/company/mesothelioma-uk https://x.com/Mesouk
Patient stories
Mesothelioma UK website
Our website remains a vital resource for anyone affected by mesothelioma. It offers clinically led accessible information on diagnosis, treatment and support services, and patient resources.
In the past year, we’ve seen:
Total page views
New users
We are committed to maintaining a trusted online hub for everyone who needs us – from newly diagnosed patients to healthcare professionals and loved ones.
20
20
24,232 125,063
Annual Report 2025
4. Awareness
Awareness is the fourth pillar of Mesothelioma UK’s strategy. Supporters and donors often tell us they want to see everything possible done to prevent future generations from facing mesothelioma.
This pillar responds directly to that call – gathering lived experience, empowering patients and families to share their stories, and using our platform to reach the widest possible audience. Our ultimate aim is twofold: to stop mesothelioma before it starts, and to drive lasting improvements in care and treatment for those already affected.
How we do this:
1. Amplifying the patient voice
We work closely with patients to help them share their experiences – turning personal stories into powerful advocacy. This year, we partnered with companies managing asbestos who, alongside becoming regular donors, helped us produce moving video footage of patients telling their story. These films are now central to our education and training programmes, ensuring the voices of those living with the UK’s asbestos tragedy are heard where they matter most.
2. Raising the profile of mesothelioma
Building a stronger media presence is vital to raising awareness of mesothelioma and the urgent need for action. Over the past year, Mesothelioma UK has engaged traditional media outlets, developed social media content, and created materials that bring the human stories behind the UK’s asbestos tragedy to wider audiences.
Our Action Mesothelioma Day campaign in June/July 2024 was a standout success, driving some of the highest engagement we’ve seen all year. Posts on Instagram and LinkedIn proved especially popular, collectively reaching almost 4,000 impressions and helping to raise vital awareness of mesothelioma.
This work was bolstered by a restructure of the leadership team and the appointment of a Digital Marketing & Content Coordinator in March 2025. While this came at the end of the financial year, we could already see the enhancements in the quality and consistency of our online content and the strengthening of our presence across platforms, particularly on LinkedIn.
We also provided direct support to journalists covering mesothelioma-related issues, connecting them with patients and families to bring depth and authenticity to their reporting. In addition, we advised on a storyline in a prime-time television programme and helped secure patient voices on breakfast television, reaching national audiences and raising the profile of the disease.
21
Mesothelioma UK
3. Championing Better Treatments, Care and Services
Raising awareness is not only about public understanding – it also means ensuring that health professionals and policymakers recognise the unique needs of people with mesothelioma. Through our partnership with the Mesothelioma UK Research Centre at the University of Sheffield, we generate evidence that shines a light on these needs, from the psychological effects of mesothelioma on veterans to the challenges faced by long-term survivors and carers.
In addition, research inspired by our nursing team and the patients they support was undertaken by the Mesothelioma UK Research Centre, revealing the prevalence of mesothelioma linked to asbestos exposure in educational settings across the UK. These insights strengthen our campaigns and provide evidence to influence policymakers, regulators, and the wider public.
By sharing these findings widely, we can influence practice, improve services, and ensure that the voices of patients and families are heard at every level of decisionmaking.
4. Campaigning for Safer Environments
In October 2024, Mesothelioma UK supported the launch of a campaign in the Daily Mail aimed at removing asbestos from schools and hospitals. This initiative was prompted by a report predicting that tens of thousands of students and teachers would die from mesothelioma due to exposure to asbestos in these institutions.
The campaign highlighted the urgent need for comprehensive action to address the ongoing risks of asbestos exposure in public buildings. Mesothelioma UK’s Chief Executive, Liz Darlison was interviewed by the Daily Mail for the campaign. We also helped to liaise with nurses, patients, unions and stakeholders to gather information for the journalists working on the campaign.
Looking ahead
----- Start of picture text -----
December 2024
----- End of picture text -----
Mesothelioma & Education Workers Study (MEWS)
Authors: Dr. Bethany Taylor, Dr. Peter Allmark and Prof. Angela Tod, Mesothelioma UK Research Centre, University of Sheffield
The Mesothelioma UK operational team has established an External Affairs Work Group to coordinate our messaging and ensure our priorities are communicated clearly and effectively. At the heart of our work, we take our lead from the patients and families we support, sharing their experiences to raise awareness of mesothelioma and the ongoing risks of asbestos exposure. In the coming year, we will focus on:
-
Amplifying patient and family voices through media, storytelling, and digital channels.
-
Highlighting key campaigns and initiatives that promote safer environments and improved care.
-
Funding and promoting research studies that enhance understanding of mesothelioma and inform improvements in treatment and support.
-
Engaging with MPs, government, and policymakers to influence change at the highest level and keep mesothelioma firmly on the national agenda.
-
Working with healthcare professionals and the wider public to strengthen understanding of mesothelioma and its impact.
Through these efforts, Mesothelioma UK aims to ensure that awareness translates into action – from earlier diagnosis and better care to prevention of future asbestos-related tragedies.
22
Annual Report 2025
5. Sustainability & Fundraising
A year of community, commitment and impact
Over the past year, the mesothelioma community has come together in powerful and inspiring ways to support our mission.
From incredible fundraising feats to steadfast volunteering and partnership work, the dedication shown by individuals and organisations across the UK has been truly extraordinary.
We are continually humbled by the passion and creativity of our supporters – whether climbing mountains, hosting bake sales, sharing stories, or simply giving what they can. Every action helps raise vital awareness and funds, and every gesture brings us closer to better outcomes for those affected by mesothelioma.
As we look ahead, we remain focused on delivering the objectives set out in our strategy. To sustain and grow our impact, we are committed to:
-
Building sustainable income to secure the future of our services
-
Strengthening governance and support structures to enable responsible growth
-
Developing and supporting a high-performing team dedicated to making a tangible difference
Our sincere thanks go to every donor, volunteer, fundraiser, trust, foundation, corporate partner, and member of our Legal Panel. Your continued belief in our work means the world to us.
Thank you for standing with us. Together, we are making mesothelioma matter.
23
Mesothelioma UK
Glitz, Generosity, and Groundbreaking Fundraising
In October, David and Ali Staley hosted the ‘Meso Live Better, Live Longer’ Ball at Edgeley Park in Stockport, an unforgettable evening filled with glitz, glamour and incredible generosity.
The event raised awareness about the dangers of asbestos and vital funds for Mesothelioma UK, bringing together friends, family and supporters. Liz Darlison, Mesothelioma UK CEO said: “It was just overwhelming how much love was in that room for David, Ali and their children, Josh and Erin. The support they have from so many is just heartwarming and the event - well, all I can say is wow! We are truly grateful to all those who have supported and helped Dave and Ali achieve so much. This is the biggest single event fundraiser ever for Mesothelioma UK! Thank you.”
Reflecting on the ball, David said: “The night could not have gone any better – we raised awareness about the dangers of asbestos, we raised the profile and vital funds for Mesothelioma UK, we invited our specialist mesothelioma medical team to join us, and the whole evening was amazing. The only complaint was having to stop dancing and vacate at midnight – as from all accounts, no one wanted to leave!!!!
“Just a huge, massive thank you to everyone who contributed, whether you were there on the night or from your kind messages of support, to generous donations via JustGiving too. The support and generosity from everyone is beyond belief and we are absolutely delighted to announce that we raised a massive £39,055.59! This will make a significant difference and for example, will fund a Mesothelioma UK specialist nurse for more than a year!’’
24 Active volunteers
Fundraising pages opened 327
24
Annual Report 2025
Community Fundraising
Year after year we are always so impressed and inspired by our wonderful fundraisers, this year is no different! Check out some of the ways our fundraisers have made an impact this year.
Challenges
London Landmarks
In April 2024, we had another brilliant turnout of keen runners ready to take on the challenge of the London Landmarks Half Marathon. Despite the surprisingly cold winds, 19 people turned up to complete the race in support of Mesothelioma UK. It was a wonderful day with a fantastic atmosphere and our Community Fundraising Team were there to cheer them on past the finish line.
Fundraising is no easy task and we are so grateful for the support and dedication from our incredible fundraisers in raising vital funds and awareness for Mesothelioma UK. Together, they raised an amazing £17,564.79 (including Gift Aid).
“Having run marathons in the past, I’m a bit of a seasoned runner and really wanted to take part in the London Landmarks Half Marathon as I have some friends that were running. I was scrolling through the list of charities and Mesothelioma UK jumped out straight away. My dad passed away from mesothelioma back in 2004, so this charity was perfect for me to fundraise for. It was one of the best feelings I’ve had running, after having a year full of injuries, and being able to cross that finish line with my dad in my thoughts. I had an amazing weekend and to raise money for a charity that means a lot made it even better.”
Dan Stanley – ran LLHM2024
25
Mesothelioma UK
Great North Run
Another wet and windy day for the Great North Run 2024 saw 29 runners lace up their shoes and push through some challenging weather conditions to support our mission and complete the 13.1 miles from Newcastle to South Shields. Whether running in memory of a loved one, raising awareness for a cause close to their hearts, or simply aiming to make a difference, they all showed great determination to complete the race in support of Mesothelioma UK. A huge thank you to everyone involved, including Lucion, a technology-led environmental services consultancy who had 10 of their employees taking part. Together, our runners raised an incredible £24,194.16 (including Gift Aid).
Fundraising Stories
Muffins for Meso
Our Muffins for Meso campaign ran throughout the month of May with over 50 bake sales being held with work colleagues, families, friends and support groups. From homemade cakes and biscuits to beautifully decorated cupcakes, each treat played a part in raising vital funds and awareness. We are so incredibly grateful to everyone for coming together and raising an amazing £5,415.63 . These small acts of kindness make such a big difference.
Fitness Feb
Our community fundraisers raised £325,565.99
Fitness February was another great success to kickstart 2025. We had supporters from all walks of life taking part and turning their workouts into a powerful way to give back. Whether walking, running, cycling, or joining fitness classes, each participant pushed themselves to raise funds and awareness in support of Mesothelioma UK. Every step, rep and mile contributed to making a difference to all those affected by mesothelioma. We are so thankful to everyone that took part and helped raise a fantastic £4,597 .
26
Annual Report 2025
Our Volunteers
At Mesothelioma UK, we are incredibly grateful to our wonderful group of volunteers who give their time and dedication to supporting us in so many ways throughout the community. Their commitment brings hope, support and positive change to so many lives. Whether supporting us virtually through proofreading and sharing on social media, or in person by helping at our events – it all makes such a meaningful and lasting impact.
Sian Thomas started volunteering for Mesothelioma UK after losing her mum, Annette, to mesothelioma in 2018.
“I’m Australian and my mum and our family were helped by Gippsland Asbestos Related Disease Support (GARDS). When I returned to the UK, I wanted to give back some of the help and support that my family had been given. Losing someone you love can leave you feeling powerless, but volunteering helps me feel that I’m playing a small, positive part.
I volunteer as a proofreader. This means I check documents like patient information leaflets to make sure they are in plain English and grammatically correct. It feels really rewarding using my skills to support the hard work of the Mesothelioma UK team. I remember how important it was to have access to clear, reliable information after mum’s diagnosis when we felt anxious and overwhelmed. I hope that when patients and their families read the leaflets I contribute to, they can easily understand the information inside and feel it has been written with them in mind.
I can do the proofreading at home, at times that are convenient for me, but I have also had the opportunity to meet other Mesothelioma UK volunteers and staff. Even though I volunteer remotely, I do feel part of a team all working together to help people living with mesothelioma.”
In November 2024, Liam Bradley, Mike Goodchild and Rob Juby set off on a 140-mile route to raise awareness of mesothelioma and vital funds for Mesothelioma UK.
Accompanied by friends and colleagues at various points along the way, they set off from Portman Road, home of Ipswich Town Football Club to Nottingham Forest’s City Ground arriving five days later in time for the Premier League game between the two sides. Mesothelioma UK assembled an enthusiastic team of volunteers to cheer, clap and spur them along over the finish line.
Thank you to all of our volunteers for their support.
22
2 76
Mesothelioma UK
Our Ambassadors
Charity ambassadors play a vital role in supporting our work and championing our mission. They help to connect the charity with the wider community, acting as a bridge that builds strong networks of professional contacts and potential partners.
Our ambassadors bring a wealth of experience from a variety of fields. Some have been personally affected by mesothelioma, while others work within the sector. With their individual expertise and passion, they not only support the charity’s goals but also actively engage with and encourage our dedicated team of volunteers.
Joining our wonderful team of Ambassadors this year are Mike Holmes , Kirsty Budenbender , Dr Roz Stanley , Richard Green and Lucy Strong .
Mike joins us having retired from Mesothelioma UK in his role as Senior Corporate Relations Officer. Mike has supported the charity for many years in his former roles, in the pharmaceutical and legal industry where he is very well known and has a deep understanding of this disease. Mike is keen to continue to support us by attending industry conferences on behalf of Mesothelioma UK.
Kirsty is the Director of DSK Environmental Ltd, which she runs alongside her husband, Dirk. The company was established in February 2020 and specialises in asbestos removal across both residential and commercial sectors, as well as industrial maintenance at waste-to-energy power stations. With a deep knowledge of the asbestos industry, Kirsty brings a wealth of experience from a diverse background, including banking, manufacturing, insurance services, and business development. She is passionate about leading from the front and takes every opportunity to raise awareness about the dangers of asbestos, as well as to promote the vital work of the charity.
Roz works as a Senior Project Manager at NHS England and will bring her expertise in data analysis and reporting to this role. Roz has been a supporter of the charity for many years working in the lung cancer team with our CEO Liz Darlison back in 2000 in an data/audit management role. Roz has always been interested in the underdog of cancers such as mesothelioma and lung which is why she is delighted to be able to help Mesothelioma UK in a voluntary capacity this year to get real value from the collection of patient data.
Richard is a Partner and Head of the Asbestos Litigation Team at Hugh James based in Cardiff. Richard also sits on the advisory board of the Mesothelioma UK Research Centre. Richard has a national reputation for asbestos related disease work and has specialised for over 15 years. Richard regularly provides training to specialist medical teams across the country and speaks at events accredited by the Royal College of Nurses and also Physicians.
Lucy is a Partner in the Asbestos Litigation Group at Hugh James and leads the team in Wales. Lucy has extensive experience working on complex asbestos related disease claims and regularly secures compensation awards for her clients. Lucy has acted for many mesothelioma sufferers who have had low level exposure, having previously worked in education and healthcare sectors. Lucy’s national reputation within her field is testament to her position on the advisory board of the Mesothelioma UK Research Centre.
28
Annual Report 2025
Fundraising Story
----- Start of picture text -----
John and Susan Harvey
----- End of picture text -----
On Saturday 3 August 2024, Keira Atherton and her father Kevin took part in a sponsored skydive for Mesothelioma UK and between them have raised over £1,500.
Kiera shared, “Nine years ago, my family lost our whole world. My grandad Roy was my family’s biggest inspiration in life and we have struggled ever since his passing. Grandad Roy worked in the painting and decorating industry for the majority of his life, eventually teaching my dad to follow in his footsteps. However, through this industry my grandad was exposed to various
dangerous chemicals and fumes, one of which was known as asbestos. Asbestos can lay dormant in people’s bodies for years then cause problems later in life. Mesothelioma is what killed our amazing best friend, and we would love to help future and current sufferers of this horrific disease in battling against it. By fundraising for Mesothelioma UK, we are hoping to raise money to aid medical research into preventions, cures and treatment enhancements against mesothelioma in the hope to save someone else’s best friend. This illness is not spoken about enough, and we hope by doing this we can also raise awareness and help as much as we can to stop the battles people are facing with mesothelioma.”
29
Mesothelioma UK
Mesothelioma UK Legal Panel
Our legal panel: Expert support, advocacy, and partnership
At Mesothelioma UK, we are proud to be supported by a dedicated Legal Panel – law firms that not only offer independent legal guidance to patients and families affected by mesothelioma but also work tirelessly to raise awareness of the disease and our charity’s mission.
The panel now includes 16 UK law firms, 10 covering England and Wales, three covering Northern Ireland and three covering Scotland.
These expert legal professionals are instrumental in helping patients recover costs for treatments that may not be available on the NHS, ensuring access to care that could be crucial in the future. While the idea of making a legal claim can feel overwhelming, our Legal Panel members provide clear, compassionate, and expert advice throughout the process. There is no cost to patients or their families, and every effort is made to minimise any stress or disruption during what is already a difficult time.
Beyond legal guidance, our Legal Panel firms are vital ambassadors of Mesothelioma UK. They help us reach more people by promoting our services including gifts in Wills and our free Will-writing service which some of our members provide, and also by supporting our work through sponsorship and fundraising. Their contributions enable us to fund specialist nurses and their education. In addition, they support and sponsor key events like our Patient and Carer Day, Awards Evening, and Ladies’ Lunch, and continue to support vital awareness campaigns.
We are incredibly grateful for their continued commitment and the difference they make in the lives of the people we support.
Corporate Partners
Working together: Our corporate partners and supporters
We are proud of the strong relationships we have built with our Corporate Partners and Supporters .
Their invaluable contributions help support our mission and our work for those diagnosed and living with mesothelioma.
Our partners and supporters contribute and support the charity in many ways, from monthly donations which is a vital source of income helping us to plan for the future enabling us to increase our specialist nursing team, to participating in Mesothelioma UK’s events and campaigns or choosing us as their charity of the year. They organise fundraisers, like quizzes, balls, team building events, coffee mornings, bake sales, dress down day and much more, all helping to raise much needed awareness and funds. We are incredibly grateful for their ongoing commitment and support, helping us make a real difference for those affected by mesothelioma.
Our Corporate Relations Team is dedicated to strengthening our existing partnerships and building on and welcoming new ones in the year ahead.
To learn more about becoming a Corporate Partner or Supporter visit our website at Mesothelioma UK www. mesothelioma.uk.com/partner-with-us or contact us corporate@mesothelioma.uk.com for more information.
30
Annual Report 2025
Gifts in Wills
We are a national charity dedicated to supporting people affected by mesothelioma through expert care, information, and advocacy.
One way to support those affected with mesothelioma is to consider leaving a gift in your Will. This year we were honoured to receive £211,351 from 14 incredible supporters who left a gift in their Will. This could fund eight clinical nurse specialists in hospitals around the UK for one year .
To make this process simple and accessible, Mesothelioma UK continues to partner with several trusted firms from our Legal Panel to offer a free Will-writing service. There is absolutely no obligation to include a charitable gift, but we warmly encourage individuals to consider supporting Mesothelioma UK in this amazing way and create meaningful change in someone’s life.
Join those who have already used this easy and free service, like Dawn McKinley who said “The free Wills service was such an easy process, no stress, just good, sound advice culminating in a fully written Will. It is such a relief to know that my wishes are officially documented. Thank you, Mesothelioma UK for providing this excellent service”.
If you would like to learn more about our free Will service or leaving a gift in your Will to Mesothelioma UK, please call us on 0800 169 2409 to request your complimentary guide, or request one online here – www.mesothelioma. uk.com/leave-a-gift-in-your-will.
----- Start of picture text -----
Patient
----- End of picture text -----
Total number of event attendees
Ladies Lunch 178
Community Dinner 124
460
31
Mesothelioma UK
Events
Patient and Carer Day
PCD & Community Dinner: Bringing the mesothelioma community together
This year marked the 19th annual Mesothelioma UK Patient and Carer Day, which was held on 10 October 2024 in Leeds.
This event is an invaluable opportunity for patients, carers, family members, nurses, healthcare professionals, legal panel members and others to come together, share experiences and learn about the latest research and care for those affected by mesothelioma.
Topics covered by expert speakers included:
-
The work of our Mesothelioma UK nurses
-
An update on benefits
-
Diagnosis and treatment of peritoneal mesothelioma
-
Updates on research studies and clinical trials
-
Mesothelioma UK short courses
-
The importance of diet for mesothelioma patients
Annual Report 2025
Stories from patients and their families included:
Sue Farrall , a keen marathon runner and weightlifter, shared her personal story of being diagnosed with mesothelioma two years ago.
Now a passionate volunteer and fundraiser, Sue and her group, the Magnificent Seven , recently completed a walking marathon raising over £10,000 for Mesothelioma UK.
Michelle Spencer shared her emotional story of how a job, taken in her youth, led to asbestos exposure, resulting in mesothelioma 45 years later.
“Life is so much more important to me. I appreciate every day. I love my family; I have wonderful friends, and I love life so much. I look at every day as another day to make memories. You have no idea what is round the corner.”
As a carer, Gail Hillson shared Our Journey including her and her husband’s experience of the Mesothelioma UK Carers Course and the value of our Support Groups.
The event welcomed around 160 attendees, including patients, carers and family members – all part of the wider mesothelioma community we are so proud to support.
Having listened to feedback from previous events, our Community Dinner was held the evening before the Patient Carer Day. This was an opportunity for patients, carers, our nurse team, our legal panel lawyers and the Mesothelioma UK team to share an evening together over dinner with no speakers, just time to meet, share stories and chat.
33
Mesothelioma UK
Ladies Lunch 2024
A Celebration of Strength, Solidarity, and Action
Total individual donations £94,520.93
On 7 March 2025, we were thrilled to host our 5th annual Ladies Lunch at the elegant Manchester Marriott Victoria and Albert Hotel – a meaningful event held in honour of International Women’s Day.
This year’s theme, Accelerate Action, focused on advancing gender equality and building safer, more inclusive environments for everyone. The afternoon brought together supporters, professionals, and patients for a powerful celebration of resilience, advocacy, and change.
Guests were treated to a delicious three course lunch, alongside an inspiring programme of speakers. Professionals from the asbestos removal industry shared how the landscape is improving for women in their field, while also addressing the urgent issue of preventing asbestos from entering landfill – a topic with profound implications for public health and safety.
One of the most moving moments of the day came from Emily-Jane Scandrett, a young mother of three, who was diagnosed with mesothelioma at just 40. Her courageous story and hopes for future change left a lasting impact on everyone in the room.
The event was a beautiful blend of heartfelt storytelling, connection, and shared purpose – a true celebration of the strength of women affected by mesothelioma and those working to create a safer world.
52 Tribute pages opened in memory of loved ones
----- Start of picture text -----
354
Online shop
orders
----- End of picture text -----
Annual Report 2025
How We Raised the Funds
Donations for Specific Funds £36,700
----- Start of picture text -----
Donated Services
& Facilities
Primary
Trading
Income
Corporate
& Trust
Non Charitable
Trading Activities
Individual
Giving
Rental
Investment
Events
Grants
Legacies
Major Donors
Campaigns & Challenges
----- End of picture text -----
Individual Giving
£518,764
Corporate & Trust
£66,639
Grants
£440,733
Major Donors £40,000
Campaigns & Challenges
£55,731
Legacies
£196,351
Events
£17,139
Non Charitable Trading Activities £241,534
Primary Trading £30,481
Donated Services & Facilities
£25,000
Investment £48,800 £43,582
TOTAL: £1,716,914
Rental
£4,260
35
Mesothelioma UK
How We Spent the Funds
Income Generation
£254,018
Patient Support £846,997
Admin & Operational £232,247
Research & Audit
£160,972
Awareness
£46,535
Information Costs £60,815
----- Start of picture text -----
Information Costs
Awareness
Research
& Audit
Income
Generation
Admin & Operational
Patient Support
----- End of picture text -----
TOTAL: £1,601,584
36
Annual Report 2025
Trustees Report
The trustees present their report with the financial statements of Mesothelioma UK CIO for the year ended 31 March 2024. (The financial statements can be found at www. mesothelioma.uk.com/accounts-and-reports).
The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
Trustees
Dr N Maskell (Chair) A L Coates Prof K Blyth Lorraine Creech Simon Purves Amanda Jones (appointed 16/9/24) Kate Williams (appointed 16/9/24) Craig Evans (appointed 16/9/24) Mike Lind (appointed 16/9/24) H Childs (resigned 27/3/24) M Waters (resigned 25/6/24) Dawn McKinley (resigned 2/12/24)
Structure, Governance and Management
Chief Executive Officer
Liz Darlison
Operational Team
Governing Document
Since re-registering in 2018, the charity has operated with a constitution and the income and property of the charity shall be applied solely towards the promotion of its objects as set out in its constitution.
Status
The organisation is a Charitable Incorporated Organisation. Launched as a resource centre in 2004 it became a Charitable Trust in 2008 and re-registered as a Charitable Incorporated Organisation in 2018.
Reference and administration details of the Charity, its trustees and advisors
Charity Number 1177039
Company Number 12541690
Principal Office
235 Loughborough Road, Mountsorrel, Loughborough, LE12 7AS
Tracey Calvert, Head of Finance Alyshia Riley, Head of Fundraising & Communications Beth Colbert, Head of Operations Leah Tayor, Head of Nursing
Jill Lemon, Corporate Relations and Fundraising Manager Megan Huxtable, Community Fundraising Manager Julie Morton, Support Services Officer Roland Ungoed–Thomas, Creative Designer Leah Scrimshire, Supporter Care Administrator Dumitrita Gulian, Finance Officer Charlotte Mason, Administrative Assistant Claire Reeves, Benefits Officer Angela Kingston-Nash, Benefits Officer Katrina Sansone-Richmond, Marketing & Communications Officer
Neil Everall, Fundraising Manager Beverley Forrester, Housekeeper Mollie Shields, Corporate Fundraising Manager (Resigned May 2024)
Hazel Curtis, Finance Officer (Resigned May 2024) Mike Holmes, Senior Corporate Relations Officer (Resigned July 2024)
Justine Bates, Individual Giving & Marketing Manager (Resigned March 2025)
Independent Auditors
Mark J Rees LLP Chartered Accountants and Statutory Auditors, Granville Hall, Granville Road, Leicester, LE1 7RU
37
Mesothelioma UK
Investment Advisors
Magma Wealth Management Limited, Magma House, 16 Davy Court, Castle Mound Way, Rugby, CV23 0UZ
Subsidiaries and Related Parties
The Mesothelioma UK Trading Company was incorporated on 31 March 2020 with company number 12541690. It is the sole subsidiary of Mesothelioma UK and exists to raise trading income for the charity. All of its profits were transferred to the charity.
Financial Overview
Basis for Preparation
The Trustees assess whether the use of the going concern concept is appropriate, i.e. whether there are any material uncertainties related to events or conditions that may cast significant doubt over the ability of the group to continue as a going concern. The Trustees make this assessment in respect of a period of at least one year from the date of authorisation for issue of the financial statements and have concluded that the group has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties about the group’s ability to continue as a going concern, thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Financial Overview
Mesothelioma UK’s income is entirely dependent on donations, legacies, and grants. These contributions are crucial for funding the charity’s research, support services, and awareness initiatives.
Gross income increased on the previous year and the charity managed to achieve a small increase in reserves at year end. The final amount raised over the year was £1,716,914 (2024 – £1,771,508).
Mesothelioma UK remains indebted to our charity partners who have provided significant funds toward the charity’s team of specialist nurses, benefits advisor and two of our research projects. A total of £433,823 was raised through these partners towards the cost of funding these areas.
Expenditure decreased from £1,658,494 in 2023/24 to £1,601,584 in 2024/25. Spending on charitable activities was £347,566, a decrease of 4.7% on the previous year. As in previous years, the largest expenditure was on the patient support pillar, which is mainly comprised of the funding of specialist nursing posts.
More detail on how we raised and spent the funds can be seen in the charts on pages 35 and 36.
To ensure the charity’s long-term financial sustainability, and with guidance from expert fundraising consultants, we have undertaken a comprehensive review of Mesothelioma UK’s fundraising strategies and resources. This has informed the development of a robust long-term plan aimed at significantly enhancing the charity’s incomegenerating capacity.
For 2024/25 the overall costs of raising funds were 14.8% of the total income (2024 – 13.7%) – similar to pre-pandemic levels. Going forward the need to invest in fundraising is essential to enable Mesothelioma UK to continue to expand its services.
Risks
Day-to-day risks for the charity are identified, treated, or managed and then monitored by the operational team. Those that pose the greatest threat to the charity are raised with the board of trustees.
Reserves
As an organisation relying almost entirely on fundraising income, our policy is to hold adequate reserves to enable us to react to any unexpected adverse events.
Mesothelioma UK’s reserves policy states that unrestricted reserves should cover, at a minimum, six months operating and research centre costs, three-month costs of our contractual liabilities and also to enable us to fulfil all our research project costs.
As of 31 March 2025, the minimum unrestricted reserves were £575,118 (31 March 2024 – £626,148) and the actual level of unrestricted reserves, excluding the value of tangible fixed assets, held by the charity was £1,039,499 (31 March 2023 – £912,911).
38
Annual Report 2025
Investments
Our investment portfolio is managed by Magma Wealth Management. As at the 31 March 2025 the portfolio stood at £544,640 This includes £532,503 of invested assets and £12,137 of cash. The value has reduced from last year due to the £250,000 withdrawal on the 9/9/25. It was decided to hold more in cash to ensure the financial security of the charity.
The investment managers brief is to manage the portfolio within agreed risk tolerance to produce long term growth in excess of Bank of England base rate plus 4% pa whilst investing in “ethical investments”, i.e. excluding specific sectors deemed to be causing harm and positively investing in companies who are seen to be benefiting the world. 2024 was a slightly positive year for investment with virtually all asset classes contributing to performance within the portfolio. Interest rates looked to be reducing globally albeit slowly which should boost asset prices.
These investments are, however, designated for longterm investing and if we review the overall portfolio strategy over a longer period of time, the portfolio is in a positive territory.
Ethical investments have again tended to underperform the general market over the last 12 months, as they are seen to be more growth orientated and are generally more sensitive to higher interest rates. More traditional industries such as banks, defense and oils fared better.
Over the longer term it is believed ethical investments still offer better prospects to outperform the wider market, it is the future , but are likely to be more volatile due to the concentration on a narrower band of investments.
Funds Held as Custodian
The charity holds funds on behalf of the UK Mesothelioma Alliance of £0 (2024 – £1,334).
Statements of Trustees Responsibilities
The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the group and the charity and of the incoming resources and application of resources, including the income and expenditure, for that period. In preparing those financial statements, the trustees are required to:
-
select suitable accounting policies and then apply them consistently;
-
observe the methods and principles in the Charity SORP (FRS 102);
-
make judgements and estimates that are reasonable and prudent;
-
state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
-
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.
The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the group and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the CIO trust deed/constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
In so far as the trustees are aware:
-
there is no relevant audit information of which the group’s auditors are unaware; and
-
the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.
Auditors
The auditors, Mark J Rees LLP Chartered Accountants, will be proposed for re-appointment at the forthcoming Annual General Meeting.
Approved by order of the board of trustees on 1 December 2025 and signed on its behalf by:
................................................. S Purves , Trustee
39
Mesothelioma UK
Looking Forward From the Chair of the Trustees Board
Mesothelioma UK is emerging from a period of tightening our belt through reviewing, prioritising and restructuring.
The vision and focus of the charity have never wavered – our engagement and dedication to patients providing a clear direction for the team to follow. It has been a challenging period but a privilege to work with the charity’s operational team over the last few years. I feel confident and optimistic for the next few years.
The year ahead will see the team maintaining all of the amazing services that the charity provides, from information, support groups, the telephone support line, the website, social media groups, clinical trials app, benefits advice and of course, our amazing nurse team. Growth of these services will all depend on the charity’s financial position. We are keen to increase our presence in every region of the UK. There are seven NHS Cancer Alliances without a Mesothelioma UK Nurse, and we have new services in Wales and Northern Ireland that we must sustain.
Mesothelioma UK has funds, thanks to a generous grant and fundraising family, that are ring fenced to support the development of our NHS mesothelioma clinical teams. The charity has been a pivotal stakeholder in the development of the Scottish Mesothelioma Network and we are working on ways to help replicate this hugely successful clinical model across the UK.
Several years ago, the charity funded a national clinical audit in mesothelioma. Demand for this to be rekindled is growing, with clinical
teams across the UK reaching out to Mesothelioma UK. We know ‘if you cannot measure it, you cannot improve it’. The charity is exploring ways and means to relaunch a comprehensive national clinical audit and is working closely with clinical teams to design the approach and content that would be most beneficial for patients.
I would like to pass on a personal thank you to the Mesothelioma UK team and particularly, my fellow trustees, for their support. From us all, please know how grateful we are to all the individuals, families, companies and groups that support, donate and fundraise for Mesothelioma UK. This is an exceptional charity. immersed in an even more exceptional community of people. Chairing the Board is a privilege and I hope this year, will see the charity’s reach and impact stride forward.
Prof N Maskell Chair of the Trustees Board
40
Annual Report 202 45
Mesothelioma UK could not do any of this without the ongoing support of our fundraisers, donors, corporate partners and legacies. Please continue to do all you do for the charity, it is your contribution that enables us to reach out and to do all we can to help those living with mesothelioma.
Mesothelioma UK Charitable Incorporated Organisation
Freephone: 0800 169 2409 Email: info@mesothelioma.uk.com www.mesothelioma.uk.com
Registered Charity Number 1177039
REGISTERED CHARITY NUMBER.. 1177039 AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 FOR MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION Mark J Rees LLP Chanered Accountants and Statutory Auditors Granville Hall Granville Road Leicester LEI 7RU
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 Page Report of the Independent Auditor5 Consolidated Statement of Financial Activities Consolidated Balance Sheet Charity Balanee Sheet Consolidated Cash Flow Statement Notes to the Consoliilated Cash Flow Statement Notes to the Consolidated Financial Statements 10 to 27 Detailed Consolidated Statement of Financial Aetivities 28 to 30
REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION Opinion We have audited the financial statements of Mesothelioma UK Charitable Incorporated Organisation (the'parent charity.) and its subsidiaries (the 'group-) for the vear ended 31 March 2025 which comprise the Consolidaied Staiement of Financial Activities, the Consolidaied Balance Sheet: the Charity Balance Sheei, the Consolidaied Cash Flow Statement and Consolidated notes to the financial statements, including a summary. of significant accounting policies. The financial reporting franiework that has been applied in their prcparation is applicable Igw and United Kingdom A¢counting Stsndards (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements.. give a trne and fair view of the state of the group's and of the parent charity's affairs as at 31 March 2025 and of its incoming resources and application of resoiirces, including its income and eXPendire, for the year then ended: have been properly prepared in accordance with United Kingdoni Generally Accepted Accounting Practice- and have been prepared in accordance with tlie requiTeinents of the Charitie5 Act 2011. Ba515 for opinion We conducted our audit in accordance with International Standards on Auditing {UK) (ISAS {UK)) and applicable law. Our respoi)sibilities ui)der those standards are I'urther described in the Auditors, resptsnsibilities for the audit of the financial Statements section of our report. We are independent of tl)e charitv in accordance with the ethical requirements tl)at are relevant to our audit of the Iinancial statementg in the UK. including the FRC'S Ethical Standard, and we have fullilled our other ethical iesponsibilities in accordai)ce with these requireinei)ts. We believe that the audit evidet)ce we have obtained is sufticient and appropriate to provide a basis for our opinion. Conclusions relating to going concern In auditing the financial siatemenis. we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have perfom)ed, we have noi identified any material uncertainties relaiing to events or conditions thaL individuallv or collectively. may casi significani doubt on Ihe group's and ihe parent charity's ability w continue as a going concern for a period of ai least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect 10 going concern are described in the relevant seciions of this report. Other information The triistccs arc responsible for the other information. The other information comprises the infomiation included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other inforniation and, except to the extent otherwise explicitly ststed in our repon, M'e do not express any forni of assurance conclusion thereon. In coiinection with our audit of the financial statements, our responsibility 15 to read the other information and, in doing so, consider whetlier the otlier infoTmation is materially incon5lStent with the finaiicial statetnents or our knowledge obtained in the audit or OtheViSe appears to be materiallj mi5Stated. If M'e identify such tnaterial ii)C0115lStencies or apparent material misstatement5, we are required to deteTmine whether this ¥iwe5 rise to a material inisstatement in the fii)ancial statements themselves. If, based oil the work we l)ave performed, we conclude that tl)ere is a material misstatement ol'this other infomiation. we are required to report that fact. We have nothing to report in this regard. Matters on whieh we are required to report by exeeption We have nothing to report in respeLt of tl)e lollowing matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report tts you if, in our opinion.. the inlonnation given in the Report of the Trustees is inconsistent in anj. material respect with the financial statements; or Ihe group has not kept adequate accounting records- Lir Ihe financial statements are not in agreemeni w'ith the accouniing records and retums: or we have nLIt received all the information and explanations we require for our audit. Page I
REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION Responsibilities of trustees As explained more fully in the Statement of Trustees, Responsibilities. the trustees are responsible for the preparation of the financial statements and for being saiisfied that theTr give a true and fair view, and for such intemal control as the Irusiees detem]ine is necessary to enable the preparatilin of financial statements thai are free from material misstaiemenL whether due to fraud or error. In preparing the fiiiancial statements, the trnstees are responsible for assessing the groups and parent charity s ability to continue as a goiiig concern, disclosing, as applicable, matters related to going conceni and using the going concern basis of accounting unless the trustees either intend to liquidate the parent or parent charity or to cease operations, or have no realistic alternative but to do so. Page 2
REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION Our responsibilities for the audit of the financial statements We have been appointed as auditors under Seciion 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulaiions made or having effect thereunder. Our objectives are to obtain reaslinable assurance about whether the financial statements as a whole are free from material misstatenient, whether due to fraud or error, and to issue a Report of the Indcpcndent Aiiditors that incliides our opinion. Reasonable assurance is g high level of assurance, but is not a guarantcc that an audit coiiducted in accordance with ISAS (UK) will always detert a material misstatenient when it exists. Misstatements can arise from fraud or error and are considered material if, individuall}. or in the aggregate. they could reasonably be experted to influence the economi¢ decisions of users taken on the basis of these financial statements. Irregularities, ii)cludingF fraud. are ii)5taiices of noii-compliance with law5 aiid rebFulations. We desiun procedures in line with our responsibilities outlined above, to detect niaterial misstatemeiits in Tespect of Iegular1tIeS, iiicluding fraud. Owing to the inherent liinitati0115 of an audit, there is an unavoidable risk that material mis5tatenients in tlie financial ststement5 may not be detected, even tl)ough the audit is properly planned and perforined in accordance with ISA'S {UK). The extent to which our procedures are eapable of deteeting irregularities, ineluding fraud, is detailed below. We obtained an understanding of the legal and regulatory Irameworks applicable to the group and the parent charity and ii)dustry in whicl) it operateg through our gei)eral commercial experience. We detemiined that the following laws and regulations were Inost signilicant." Charities SORP (FRS 102). We enquired of management conceming ihe group's and parent charity's policies and procedures relating tLI'. the identificaiion and compliance with laws and regulations. the detection and response io ihe risks of fraud. Ihe internal controls inherent within the group and parent charity to mitigate fraud risk and non-compliance to laws and regulations. We enquired of managemenL whether they were aware of any instances of non-compliance with laws and regulations or herher they had any knowledge of actual, suspected or alleged fraud. We communicated relevant laivs and regulations and potential areas of fraud to all audit team members. We remained alerr to any indications of fraud or non-compliance with laws and regulations throughout the audit. We have detennined that the principal risk areas where material irregularities coiild occur were related to posting manual journal entries to maiiipiilate financial perfonnaiice, income reco(Tnition and 5igiiificant one-off or unusual transactions. Our audit procediires were designed to respond in particular to these identified risks (including non-compliance with laws and regulations and fraud). Our audit procedures included but were not limited to.. review of a sainple of sale5 invoices and monies received from the income streams to ensure income has been accuratel), recorded aiid to cotjfirin amount5 are recobFni5ed in the correct period. A review of laws and regulations the charity is subject to. followed by compliance checks and discussion with managen)ent to ei)sure no insthnces of non-compliance. Addressing the risks of fraud through management override of controls by perfomiing a journal entry test. We did not identify any maiters during the course Lif our work that indicated non-compliance '1th laws and regulaiions or relating to fraud. Page 3
REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website ai www.frc.org.uklauditorsresponsibilities. This description forms partof our Reportof the Independent Auditors. Use of our report This report is made solelv to the charity's trustees. as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit WOTk lias been undertaken so that we might state to the charity's trustees those matters we are required to state to theni in an auditOTS' report and for no othcr purpose. To tlic fullest eytent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed. Mark J Rees LLP Chartered Accountants and Statutory Auditors Eligible to act as an auditor in teTm5 of Section 1212 of the Coinpaiiies Act 2006 Granville Hall Granville Road Leicester LEI 7RU Date.. Page 4
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025 2025 Total funds 2024 Total funds Unrestricted fund Restricted funds Notes INCOME AND ENDOWMENTS FROM Donarions, grants and legacies 879,605 517,452 lJ97,057 1,532,402 Charitable activities- primary trading income 5,481 25,000 30,481 5,268 Other trading activities Inve5tnient inconie Other income 241,534 43,582 4,260 241,534 43.582 4,260 203,225 26,353 4,260 Total ,174,462 S42,4S2 1,716,914 1,771,508 EXPF.NDITURE OIY Raising funds 242,938 11,080 254,018 243.177 Charitable activities Infonnation Expcnses A..arelless Costs Research & Audit Costs Patient Support Costs Administration and operational ¢osts 60,190 45,910 59,812 413,291 230,708 625 625 101,160 433,706 1,539 60,815 46,535 160,972 846,997 232,247 65,936 79,767 137,708 873,234 258,672 Total ,052,849 548,735 1,601,584 1,658.494 Net gains Lin investments 3,463 3,463 60,065 NET INCOME/(EXPENDITURE) 125,076 (6,283) 118,793 173,079 RECONCILIATION OF FUNDS Total funds brought fOard 925,220 358,065 1.283,285 1,110,206 TOTAL FUNDS CARRIED FORWARD 050,296 351,782 402,078 1283 285 The notes form part of these financial statements Page 5
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CONSOLIDATED BALANCE SHEET 31 MARCH 2025 2025 Total funds 2024 Total funds Unrestricted fund Restricted funds Notes FIXED ASSETS Tangible assets Investnients 10,796 800,279 10,790 800,279 12.309 791,075 811,075 811,075 803.384 CURRENT ASSETS Debtors Investments Cash at bank and in hand 19 20 168,524 168,524 229.149 100.738 359,030 251,293 351,783 603,076 419,817 351.783 771.600 688.917 CREDITORS Amounts falling due within one year 21 (180,597) (180,597) 1209.016) NET CURRENT ASSETS 239,220 591,003 479901 TOTAL ASSETS LESS CURRENT LIABILITIES 1,050,295 351,783 1,402,078 1,283,285 NET ASSETS 1050.295 351.783 1402 078 1283 285 FUNDS Unresiricted funds Restricted funds 23 1,050,295 351,783 925.220 358.065 TOTAL FUNDS 1,402 078 1283 285 The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by.. .1911112025................................. S Purves - Trustee N M8skell Trustee The notes form part of these financial statements Page 6
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CHARITY BALANCE SHEET 31 MARCH 2025 2025 Total funds 2024 Total funds Unrestricted fund Restricted funds Notes FIXED ASSETS Tangible assets Investnients 111,796 800,280 10,796 800,280 12.309 791,076 811,076 811,076 803.385 CURRENT ASSETS Debtors Investments Cash at bank and in hand 19 20 154,243 154,243 228.348 100.738 359,030 251,293 351,783 603,076 405,536 351.783 757.319 688.116 CREDITORS Amounts falling due within one year 21 (166,317) (166,317) 1208.216) NET CURRENT ASSETS 239,219 591,002 479 900 TOTAL ASSETS LESS CURRENT LIABILITIES 1,050,295 351,783 1,402,078 1,283,285 NET ASSETS 1050.295 351.783 1402 078 1283 285 FUNDS Unresiricted funds Restricted funds 23 1,050,295 351,783 925.220 358.065 TOTAL FUNDS 1,402 078 1283 285 The financial statements were approved by the Board of Trustees and authorised for issue on and M'ere signed on irs behalf by.. 1911112025................................ S Purves - Trustee N Maskell - Trustee The notes form part of these financial statements Page 7
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025 2025 ?024 Notes Cash flows from op¢rating activities Cash generated froni operations 108,378 2,655) Net cash provided byl(used in} operating activities 108,378 2.655) Cash f]ows from investing activities Purchase of tangible fixed assets Movement in fixed asset investmenis Movement in curreni assei investments Interest received (2.910) (5.742) 100,738 43.582 13,573} 2,525 26,353 Net casl) provided by investing activities 135668 Change in cash and cash equivalents in the reporting period Cash and eash equivalents at the beginning of the reporting period 244,046 22,650 359,030 336,380 Cash and cash equii'alents at the end of the reporting period 603,076 359.030 The notes form part of these financial statements Page 8
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025 RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES 2025 2024 Net income for the reporting period (as per Ihe Statement of Financial Activities) Adjustments for: Depreciation charges Gain on investTnents Interest received Decreasel{increase) in debtors (Decreasel.. increase in credito[5 118,793 173.079 4,424 (3,463} (43,582} 60,625 28,419 5,121 (60,065) (26,353} {106,757} Net Cash provided byl(used in) operations 108,378 2,655) ANALYSIS OF CHANGES IN NET FUNDS At 1.4.24 Cash flow At 31.3.25 Net cash Cash at bank and in hand 359.030 603.076 3S9 030 Liquid resources Dcposits included in ¢ash Current asset investments 100,738 100,738 100,738 100,738 Total 4$9.768 143J08 603,076 The notes form part of these financial statements Page 9
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS FOR THE YEAR ENDED 31 MARCH 2025 ACCOUNTING POLICIES Basis of pr¢paring Ihe financial s¢al¢rn¢nts The financial statements have been prepared in accordance with the Charities SORP {FRS 102)'Accounting and Reporting b}, Charities.. Siatement of Recommended Practice applicable to charities preparing their accounts in accordaiice with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021, Fiiiancial Reporting StandaTd 102'Tlie Financial Reporting Standard applicable in the UK and Republic of Ireland, and the Charities Act 2011. Mesothelioma UK CIO meets the definition of a public benefit entity under FRS 102. The financial statements have been prepared uiider tlie historical cost convention, with the exception of investments which are included at market value, as inodified by the revaluatioii of certain assets. The ¥roup financial statetnents consolidate the financial statements of Mesothelioina UK CIO aiid its subsidiary up to 31 March 2025. Reelassifieation of Prior Year Figures The presentation of certain incon)e categories has been revised in the current year io better retlect the nature of the charity's activities. Comparative figures have been reclassified accordii)gly. These changes have no impact on the nei movement in funds or the financial position reported for the prior year. Ineome All income is recognised once the Group has entitlement to the income, it is probable that the inclime will be received and the amount Lif inclime receivable can be measured reliably. For legacies, entitlement is iaken as the earlier of the date on which either.. the Group is aware of probate has been granted, the estate has been finalised and notification has been made by the execuiorfsl to the Group Ihat a distribution .111 be made, or 'hen a distribution is received from the estate. Receipt of a legacy, in whole or in parL is only considered probable when the amount can be measured reliably and the Group has been notified of the executor's intention to mgke 8 distribution. Where legacies have been notified to the Group, or the Group is aware of the graniing of probate. and the Criteria for income recognition have noi been met, then the legacy is treated as a contingent assei and disclosed if material. Doiiated Seice5 or facilities are recotwnised when tl)e Group has control over the item, any conditiot]s associated ith the dot]ated item have been met, the receipt of economic benefit froni tl)e Use of the Groiip of the time is probable and that econoinic benefit can be measured reliably. It] accordance with the Charities SORP IFRS 102), the get]eral volunteer time is not recognised and refer to the Trnstees, report for more info]n)ation about their coi)tribution. On ieLeipt, donated professional services aiid donated facilitles dre reLogni5ed on tl)t basis of the value of the ¥ift to the charity whiLh is the amount tlie Group would liave been willing to Pdy to obtain service5 or fiicilities or equivdlent ecoiioniic benefit on tlie open market; a COTrespoiidiii¥ amouiit is then recognised in expenditure in the period of receipt. Grants are included in the Con5o1idated Statement of Financidl Activitie5 on a reLeivable basis. The balaiice of income received for specific purposes but not expended during the period is shown in then relevant funds on ihe Balai)ce sheei. Where inconie is received in advance ot eniitlement of receipt, its recognition is deterred and included in crediwrs as deterred income. Where entitlement occurs before income is received, the income is accrued. Income tax recoverable in relaiion to donations received under Gift Aid or deeds of covenant is recognised at the lime of the donation. Page 10 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 ACCOUNTING POLICIES- continued Incorne- Continued Iticome tax recoverable in relation to investmenr income is recognised at the time the investment income is receivable. Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the setvice. Expenditure Expenditure is recognised once tliere is a legal or constructive obl j(Tation to transfer econoniic beiiefit to a third party, it is probable that a transfer of economic benefits Thill be required in settlemeiit and tlie aniount of the obli¥ation can be measured reliably. Expeiiditure is cla55ified by activity. The costs of each activity are made up of the totsl of direct Costs aiid Shared cost5, including 5UPPOrt Costs involved iii undertaking each activity. Direct Costs attributsble to a 5in¥le activit), are allocated directly to tliat activit),. Shared cost5 which contribute to inore than one activit), and support Costs which are not attributable to a single activitv are apportioned between those activities on a basis consigient with the use of resources. Central staff costs are allated on the basis ol'time spenL ai)d depreciation charges allocated on the portioi) of the asset's use. Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charithble activities. Support costs are those costs incurred directly in support of expendiiure on the objects of the charily and include project manageinent carried out at Headquarters. Costs of generating funds are cosis incurred in attracting voluntary, income, and Ihose incurred in Irading activities Ihat raise funds. Chariiable activities and Governance costs are cosis incurred on the charity's operations, including support costs and costs relaiing to the governance of the charity apportioned to charitable activities. Tangible fixed assets All assets costing more than £500 are capitalised. A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate Ihat the carrying value of an J. fixed asset may not be recoverable. Shonfalls between the carrying value of fixed assets and their recovergble gmounts gre recognised gs impairments. Impairment losses are recognised in the Statement of Financial Activities. Tangible fLxed assets are carried at Costs, net of depreciation and any provision for impairnient. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives. Depreciation is provided on tl)e followin¥ bases.. Fixtures and fittin¥s 15Q/o reducing balance Coniputer equipnient 33.33Q/o reducing balance Fund #ceounting General fuiid5 are unrestricted funds M'hich are available for use at the discretion of the Trustees in furtlieraiice of Ihe general objectives ol-the Group and which have not been designated tor other purposes. Restricted funds are funds which are to be used in accordance with specific restrictions imposed b}, donors or which have been raised b5, the Group for pariicular purposes. The cosis ol- raising and adininisiering such funds are charged againsi the specilic fund. The aim and use of each restricted fund is set out in the notes ihe Iinancial sthtements. Taxation The chariiy is exempt from corporation tax on lis charitable activities. Pagell continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 ACCOUNTING POLICIES- continued Pension cosls and other po$t-r¢tir¢rn¢nl b¢nefit$ The Group operates a defined coniributioii pension scheme and the pension charge represents the amounts payable by rhe Group to Ihe fund in respect of the period. Fixed a55et investments Listed investments aTe a form of financial instrument and are initially recognised at their traiisaction cost and subsequently ineasured at fair value at the Balance sheet date. Investment gains and losses, whether realised or llnreali5ed, are combined and preseiited a5 'GaIn(LOSses) on investments, in the Consolidated statement of financial activities. Investments in 5ub5idiarie5 are valued at cost less provision for impaiTment. Other investtneiits con5lSt5 of fixed teTm deposit accouiits with high street bank5 and building societies that mature more than one year froin the retx)rtin¥ date. Interest Reeeivable Interest on funds held on deposit is included when receivable and rl)e amount can be measured reliabls, bj. the Charity.: this is i)ornJally upon notification of the interest paid or payable by the institutioi) with whom the funds are deposited. Debtors Trade and other debtors are recognised at the settlement amount after any irade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. Cash at bank and in hand Cash at bank and in hand includes cash and shlin-temi highly liquid invesiments with a short maturity of Ihree months or less from the date of acquisition or opening of the deposit or similar account. Liabilities and provisions Liabilities are recognised when there is an obligation at the Balance sheei date as a resiilt of a past event, it is probable thai a transfer of economic benefit will be required in settlement, and the amount of Ihe settlement can be estiniated reliably. Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the atnount it has received as advanced paynients for the goods or services it must provide. Provisions are measured at the best estimate of the nOU11tS required to settle the obligation. Where tl)e effect of the time value of money is material, the provision is based on the present value of those nO[li)tS, discoiinted at the pre-tsx discoLllIt rate that refleLt5 the risks specific to the liability. The unwinding of thediscount is recognised in the Consolidated statement of fiiianLial activities a5 a finaiice cost. Current asset investments CUe11t asset investment5 are cash or cash equivalents with a maturity date niore thali three months after the reportiiig date but less than one year valued at cost. Going Coneern The Trustees access whether the use of going concern is appropriate i.e. whether there are anj material ui)certainries related to events or conditioi)s thai may cast significant doubt over the ability of the charit}, to coniinue as a going concern. The Trustees make this assessmeni in respect of a period of at least one year Irom Ihe date of authorisation for issue of the Iinancial staiements and have concluded thai the chariti. has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties about the charity's ability to continue as a going concern, thus they continue to adopt ihe going concem basis of accounting in preparing the financial statsments. Page 12 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY Estimates and judgements are continually evaluated and are based on historical experience and other faciors, including expectstions of future events that are believed to be reasonable under the ¢ircumsian¢es. Critical accounting e5tirnate5 and a55umption5: The Group makes estimates aiid assumptions concerning tlie ture. The resulting accounting estimates and assuniptions M'ill, by definition, seldoni equal the related actual results. The estiinates and assumptions that have a sigiiificant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. Useful economic lives of tangible assets Tlie aiinual depreciation charge for tangible fixed assets is sensitive to chan¥e5 111 the estimated useful economic lives and residual value5 of the assets. The use1 ecoiioniic lives and residual value5 are rea5se5sed aniiuallv. Tliey are ainended when nece55ary to reflect current e5timate5, based oli techiiolo¥ical advancemeiit, future investmei)ts. economic uiilisation ai)d the phjgical condition of the assets. See note 16 lor the carrying amount of the Iixture and fittings and computer equipment and note I for the useful economic lives for each class ol'assets. Residual legaeies There is some uncertainty in the value ol'residual legacies recognised due io the time lapse between when probate has been granted and the fii)al distribution is made. Donated seFviees and facilities The Group has been donated the use of the premises they operate from. The fair value of the dL)naied faciliiy has been arrived at based on the amount the Group would pay in the open market for an altemaiive. This has been calculated on an esiimaied average rate per square foot. While this is considered a reasonable reliable approach Ihere is some uncenainty due to multiple factors affecting the rental value of the property, including the size, the age and demographical area. DONATIONS, GRANTS AND LEGACIES 2025 2024 Dot]ations Legacies Grants Dot]ated services at]d facilities 734,973 196,3SI 440,733 25,OIMI 683.612 220.913 602.877 25,000 1,397,057 1,532.402 Donated services and facilities comprise of the use of the premises the Group operates from. The donation represents the deemed market rent of the propety. Page 13 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 DONATIONS, GRANTS AND LEGACIES- continued Grants received included in the above, are as follows.. 2025 2024 Amied Forces Covenant Readleys for provision of beiiefits advisor utQ Goveriimeiit Covid Medical Research B&CE Charitable Trnst for benefits advisor Meniorials Grant Sclienie to cover Me50 UK'5 AF Memorial VA T costs Grant5 for the provi5ioii of Iiursing service5 froin.. 712 6.736 133,178 9,733 15,OIMI 4.040 HASAG LASAG Readley5 Mavis Nye loundation Action on Asbestos Asbestos Action SWASAG Meso UK'S Legal Panel MAPS Benevolent fund Clydebank Asbestos Group Meso UK Legal Partner ASCE GMAVSG Grants for research projects from.. HASAG Erase-meso 87,344 57,379 22,278 22,0(Ml 150.225 22,000 19,952 44,000 48,000 11,498 31,124 25.000 24,000 39,337 25,0(H) 36,690 22,0( 5.382 5.000 37,191 36,221 440,733 602,877 OTHER TRADING ACTIVITIES 2025 2024 Trading income Events income One Lottery income Shop income 198,806 30,516 4,242 106,076 20,454 4,242 241,534 203,225 The trading income represents income from Mesothelioma UK commercial relationships which includes.. Conimission from the UK National Asbestos Re¥ister liicome raised from niembers of Mesothelioma UK Trading Ltd's legal panel: who make payment to Mesothelioma UK Trading Ltd, in retuni for the inclusion tsf tl)eir naine and logo on our w'ebsitt and legal advice leaflet. Their logo is also included oli the Mesothelioina Matters magazine, and they each have space foi one article in one of Ihe quarterly magazines per year. Page 14 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 INVESTMENT INCOME 2025 2024 Deposit accouni interest Dividends received 37,891 5,691 21,631 4.722 43,582 26.353 OTHER INCOME 2025 2024 Rental income 4,260 4,260 INCOME FROM CHARITABLE ACTIVITIES 2025 2024 ADDRI inctstne Speaker5 fees Events income 25,0(Ml Fuiids have been provided to Mesotl)elioma UK to cover the costs incurred 5UPPOrting the Au5traliaii Dust Disease Research Institute (ADDRII 10 develop resources, particularl!, specialisi mesothelioma nursiiig across Australia. RAISING FUNDS Raising donations and legaeies 2025 2024 Staff costs Will 'ritIng Stripe and online giving fees Christmas card purchases Fundraising costs Travel expenses Charitable events Wcbsite and social media Online shop expen%es UHL staff cost5 Head of nursing 140,930 3,027 124.148 1.817 11,897 1.869 32,464 193 17,639 3,110 3,049 43,111 ,992 29,155 182 18,152 3,301 1,699 36,407 252 J81 241,522 Other trading expenses 202S 2024 Administration expenses Page 15 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 CHARITABLE ACTIVITIES COSTS Direct Costs (see note l O} Support costs (see note I l) Toials Information Expenses A wareness Costs Research & Audit Costs Patient Support Costs Administration and operational costs 60,815 46,535 160,972 846,997 60,815 46,535 160,972 846,997 232,247 232,247 1,115,319 232,247 1,347,566 10. DIRECT COSTS OF CHARITABLE ACTIVITIES 2025 2024 Staff costs Provision for nursing services Nurses meetings Website and social Inedia Patient support 5undrie5 and other support cost5 Patient travel Printing and design magazine Project Wales Research centre main award Other research costs Armed Forces project expenses Infonnation expenses Patient carer da}, Awareness costs Travel expenses Team leaders Research grants Head of nursing Educational event expenses UHL staff costs 192,831 635,825 2,795 13,201 5,795 198,529 649,660 5,200 12,442 5,464 ,412 4,218 140 74,312 625 2,438 (1,639) 578 19,611 11,482 11,253 1.671 47 84,144 108.289 40,058 6,006 6,090 54,034 53,095 44,726 2,738 9,102 1,115,319 1,156,645 Page 16 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 SUPPORT COSTS Governance costs Other Totals Administration and operational costs 224,145 8,102 232,247 Support costs, included in the above, are as follows.. 2025 2024 Wages Social security Pen510115 Riltes aiid water Insurance Telephone p0sge and stationery Repairs and maintenance Legal and professional fees 116,461 8,828 8,275 3,449 1,147 3,943 1,700 1,880 3,339 140,589 10,151 9,613 4,709 1,032 3,905 1,674 751 6,746 Govemance Travel expenses Investment manager costs Training Subscriptions IT support and other IT costs CRM expeiises Marketing and adverts Bank charges Office expenses Head of nursing Rent Depreciation of tangible fixed assets Auditors, remuneration 4.455 513 6.022 106 4,888 10.597 7,349 2,576 862 2,159 2,225 25,000 5,120 7,630 87 704 1,938 12,439 8,481 4,859 ,265 2,077 2,485 25,OIHI 4,424 8,102 232,247 258,672 12. NET INCOME/{EXPENDITURE) Net incomel{expenditure) is stated after char(TjntTI(crediting)'. 2025 2024 Depreciation- owned assets 13. AUDITORS, REMUNERATION 2024 Fees pa5Jable to the charity's auditors for the audit of the charity's financial statements Page 17 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 14. TRUSTEES, REMUNERATION AND BENEFITS There M".ere no trustees, remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024. Trustees, expenses For the year ended 31 March 2025, there was £nil (2024.. £191) paid to Mr N Maskell and there was £115 (2024.. £50) paid to Ms L Creech. 15. ST AFF COSTS 2025 2024 Wage5 and salarie5 Social security Costs Other pension costs 403,169 32,964 420,504 i3,685 467,425 483,030 Remuneration of kev management personnel Ke}. tnaiia¥einent personnel are deemed to be those havin¥ authority and responsibility, dele¥ated to them by the Irusiees for planning.- directing and controlling the activities of the charity. The tothl employee benefits of the key managen)ent personnel of the charity amounted to £210,642 (2024: £112,415). The average monthly number of employees during the year was as follows.. 2025 15 2024 16 Support staff The number of employees 'hOSe emplL)yee benefits (excluding employer pension CLlSts} exceeded £60.000 was.. 2025 2024 £70,001- £80,000 Page 18 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 16. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES- 31 MARCH 2024 Unrestricted fund Restricted funds Total funds INCOME AND ENDOWMENTS FROM Donations, grants and legacies 888.469 643,933 1,532,402 Charitable activities- primary trdding income 5,268 5,268 Other trading activities Investment iiicoine Other income 203,225 26,353 203,225 26,i53 Total ,127,575 643,933 1,771,508 EXPENDITURE OIY Raising funds 243.177 243.177 Charitable activiti¢5 Iiiforniation Expenses A wareness Costs Research & Aiidit Costs Patient Support Costs Adininistration aiid operational costs 65,936 60,123 59,511 360.705 258.672 65,936 79,767 137,708 873,234 258 672 19,644 78,197 512,529 Total 1,048,124 610,370 1,658,494 Net gains Lin investmenis 60.065 60,065 NET INCOME 139,516 33,563 173,079 RECOP4CILIATION OF FUP4DS Total funds brought forward 785.704 324.502 1,110,206 TOTAL FUNDS CARRIED FORWARD 925 220 358 065 1,283 285 Page 19 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 17. TAf44GIBLE FIXED ASSETS- GROUP Fixtures and fittings Computer equipment Totals At l April 2024 Additions 3,787 33,5S4 2,910 37,341 2,910 At 31 March 2025 3,787 36,464 40,251 DEPRECIATION Ai l April 2024 Charge for year 22,087 4,297 25,032 4,423 126 At 31 MarLh 2025 NET BOOK VALUE At 31 March 2025 716 10,080 At 31 March 2024 842 TANGIBLE FIXED ASSETS- CHARITY Fixtures and fittings Computer equipment Totals COST At l April 2024 Additions 3,787 33,554 2,910 37,341 2,910 At 31 March 2025 3.787 36,464 40,251 DEPRECIATION At l April 2024 Charge for year 2,945 126 22,087 25,032 At 31 March 2025 NET BOOK VALUE At 31 Marcli 2025 716 10,080 At 31 March 2024 842 Page 20 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 18. FIXED ASSET INVESTMENTS-GROUP 2025 2024 Shares Other 544,641 255,638 791,075 800,279 791.075 Additional infom)ation as follows.. Cash and settlenients peiiding Listed investments Totals MARKET VALUE At l April 2024 Additions Disp05a15 Revaluations 774,647 91,771 (337,378) 3,463 16,428 343,069 (347,359) 791,07S 434,840 (684,737) 3,463 At 31 March 2025 $32,503 12,138 $44,641 NET BOOK VALUE At 31 March 2025 532,503 12,138 544,641 At 31 March 2024 774,647 16,428 791,075 FIXED ASSET INVESTMENTS- CHARITY 2025 2024 Shares Other S44,642 255,638 791.076 800,280 791,076 Additional infotynation a5 follows.. Shares iii group undertakings Cash and settlenients pendin¥ Listed investTneiits Totals MARKET VALUE At l April 2024 Addiiions Disposals Revaluations 774,647 91,771 (337,378) 16,428 343,069 (347,359) 791,076 434,840 (684,737) At 31 March 2025 532 503 544 642 NET BOOK VALUE At 31 Marcli 2025 532,503 544,642 At 31 March 2024 791076 Page21 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 FIXED ASSET INVESTMENTS- CHARITY- continued Cost or valuation at 31 March 2025 is represented by.. Shares in group undertaking5 Cash and settlements pending Lisl¢d inve5tment5 Totals Valuation in 2025 Cost 532,503 532,503 12,139 12,138 532,503 12,138 544,642 The charity's investments at the balance sheet date in the share capital of companies include the following.. Mesotheliorna UK Trading Liniited Registered office.. 235 Lou¥hborough Road, MouiitsotTel, Lou¥hborou¥h, LE12 7AS Company number.. 12541690 Nature of busines5.' Sponsorship and advert15in¥ sales Class of share= Ordinary holdiiig 2025 2024 Aggregate capital and reserves Profit for the year 197,169 164,421 FIXED ASSET INVESTMENTS-GROUP AND CHARITY Investments (neither listed nor unlisted) were as follows.. 2025 2024 Bank deposits 255,638 Other investments consist5 of fixed tem) deposit account5 Wlth high street banks and building societie5 which mature iii Inore than a year. There were no investJneiit assets outside the UK. 19. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR- GROUP 2025 2024 Trade debtors Other debtors Prepayments and accrued income 28.431 10.449 129,644 14,599 5,817 208,7i3 168 $24 229 149 Page 22 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 19. DEBTORS: AMOUNTS FALLING DUE WITHIiN ONE YEAR- CHARITY 2025 2024 Trade debiors Amounts owed by group undertakings Other debtors Prepa)'Tnents and accrued income 10,168 3,982 10,449 129,644 13,798 5,817 208,733 154,243 228,348 20. CURRENT ASSET INVESTMENTS- GROVP AND CHARITY 202S 2024 Bank deposlts 100.738 CuTrent asset investments consists of fixed rate dep051ts M'ith hi¥h Street banks ai)d buildii)g societies that mature niore than 3 tnonths after the reporting date but less than 12 months. 21. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR- GROUP 2025 2024 Trade crediiors Social security and other taxes Other creditors Accruals and deferred income 84,241 17,758 4,676 73,922 65,983 14,376 4,954 123 703 180 S97 209016 CREDITORS: AMOUNTS FALLING DUE WITHJN ONE YEAR- CHARITY 2025 2024 Trade crediiors Amounts owed to group undertakings Social security. and other iaxes Other creditors Accruals and deferred income 84,241 65,983 10.105 9,318 4,676 68,082 4,954 117.863 166 208,216 Within accruals and deferred income are funds received in advance from fundraising challenges vet IL) take place at the year end. The deferred income is £16,163 (2024.. £11.097). The events are expected to take place in ?025126. 22. LEASING AGREEMENTS-GROUP AND CHARITY Minimum lease payments under non-cancellable operating legses fall due as follows.. 2025 2024 Within one year Be.e¢n one and five years In more than five year5 25,1100 loo,0 25,000 i (10,000 162,093 187,093 Page 23 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 23. MOVEMENT IN FUNDS Net nJoi'¢m¢nt in funds At 31.3.25 Al 1.4.24 Unrestricted fund5 General fund 925,220 125,075 ,050,295 Restricted funds Graiits and donation5 for nurses Project Nl Grants aiid donati0115 for research Grants aiid donation5 for other restricted projects Project Wale5 Mick May Meinorial Fund Commonwealth Mesothelioma Research Network 31,881 39,074 149,183 16,277 48,1S8 39,074 (94,119) 8,653 19,801 109,473 12,624 (8,246) 52,599 21,277 11,5S5 162,072 358 06S 82 341783 TOTAL FUNDS ,283,285 118,793 ,402,078 Net movement in funds, included in the above are as follows.. Incomi1)¥ resources Resource5 expended Gai115 and 105se5 Movetnent in funds Unrestricted funds General fund 1,172,825 {1,051,213) 3,463 125,075 Restrieted funds Granis and doi)ations for nurses Grants and donations for research Granis and donations for other restricted projecis Project Wales Mick May Memorial Fund Commonwealth Mesothelioma Research Network 418,834 7,041 (402,557) (101,160) 16,277 (94,119) 37.968 1.010 52,599 (2S,344) (9.256) 12,624 (8,246) 52,599 25,000 10,417) 14,583 542.452 548.734 6.282 TOTAL FUNDS ,718277 ,599 947) 118793 Page 24 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 23. MOVEMENT IN FUNDS- continued Comparatives for movement in funds Net movement in ndS At 31.3.24 At 1.4.23 Unrestricted fund5 General fund 785,704 139,516 925,220 Restricted funds Grants aiid donati0115 for nurse5 Arined Forces Graiit Project Nl Grants aiid donat10115 for research Grants ai)d donations for other restricted projects Project Wales Mick May Memorial Fund 141,276 1,474 35,714 1109,395) (1,474) 3.360 149,183 31,881 39,074 149,183 24,826 11,739 109473 (16,173) 8,062 8,653 19,801 10947J 324 502 358 065 TOTAL FUNDS 1,110,206 173,079 1,283,285 Comparative net tnovement in funds, included in the above are as follow5.. Incoming resources ResouTce5 expended Gain5 and losses Movetnent in fui)ds Unrestricted funds General fund 1.125,921 {1.046,470) 60,065 li9,516 Restricted funds Granis and donations for nurses Armed Forces Grant Project Nl Granis and donations for research Granis and donations for other restricted projecis Project Wales Cost-Benefit study 385.747 712 3,360 206,590 1495.142) (2,186) 1109.395) (1,474) 3,360 149.183 (57.407) 17,023 10,500 20,000 (33,196) (2,438) 20,000) (16,173) 8,062 643,932 610,369 33,563 TOTAL FUNDS 1769 85i 1.656 839) 173 079 Unrestricted funds are available to be spent for any purposes of the charity. Page 25 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 23. MOVEMENT IN FUNDS- continued Purposes of restricted funds Grants and donations for nurses Variou5 grants and donations were received during the year towards the cost of the Mesothelioma UK clinical nurse specialists and teain leaders. Project Nl These are ring-fenced donations restricted for Mesothelioma UK to establish or expand services across Northern Ireland. Mesothelioma UK clinical nurse specialists have been recruited for Northern Ireland who l[l lead the development of appropriate 5ervice5. Project Wales Tliese are riiig-fenced donati0115 restricted for Mesothelioma UK to establish or expand services across Wales. Mesothelionia UK clinical nurse specialists have been recruited in tlie region who will lead the development of appropriaie services. Miek May Memorial Fund Most ol'ihe funds in the MMMF were a grant from the Schroder Foundation. This is for use under the'lmproving Outcomes and Experience, pillar, to ensure patients have equitable access to the best treatmenL care, infomation ai)d support including helping to build a comprehensive mulii-disciplinary team approach and evidenced based care paihways and guidelines which are fundamental to achieving improved outcomes and experiences. Commonwealth Mesothelioma Researeh Network Mesothelioma UK are supporting the Australian Dust Disease Research Instituie (ADDRI) to develop resources, particularly specialist mesothelioma nursing. across Australia. In addition the two organisations have established an international research network and togeiher they plan io develop a menu of resources and ei'ents to help share mesothelioma specific learning, expertise and knowledge across all countries in the commonwealth. Grants for R¢5¢8rch Donations were received restricted for both general research and specific research projects. Grant5 for other restricted projects Other donatioiis M'ere received and restricted for the education of tl)e t]urse5, tom'ards the ndIng of Me50thelioma UK benefits advisors, towards the funding of support groups and to help towards tTavel costs. 24. EMPLOYEE BENEFIT OBLIGATIONS Tlie charity operates a defined LOTltribution pension scheme. Tlie a55ets of the scheine art Iield separiltely from those uf the Group iii an iiidependtntlv administered fund. The pension c05t Lharge5 represent the LOTitributions paydble by the charity to the fund in the Jear Lind iimount to £31,292 (2024.. £28,841). At tlie balance sheet date £4,0 {2024.. £3,620} were payable ts) the fund and are iiicluded in Lreditors. Page 26 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 24. CONTINGENT ASSET The Group has been notified of an entitlement to legacies of which the Group is unable to measure reliably the value of amounts due and therefore no provision has been made in the accounts. 25. RELATED PARTY DISCLOSURES A L Coates is a TNstee of the parent charity and a partneT of Irwin Mitchell Solicitors. Duriiig the period, £64,059 (2024.. £36.828) was receivable by the gTOUP from Irwin Mitchell Solicitor5 being £27,600 (2024.. £24,000) sponsorship income plus £36,459 (2024.. £1 ?,8281 from ndraISing events and donations. Also. during the peTlOd, the group acquired will writing and other professional services from Irwin Mitchell Solicitors at a cost of £2,204 (2024.. £1,547). D McKinley was a Trustee of the parent charit),: resi¥nin¥ on 31 Decetllber 2024, and Senior Executive Officer of the British Thoracic Oiicology Group IBTOG}. Duriiig the period, BTOG paid rent to the parent charity of £4,260 {2024.. £4,260} aiid received aniount5 for recharged expe115es of £36012024.. £194). C Evans is a frustee of the parent charity and Chief Operating Officer at UK Asbestos Training Association Ltd (UKATAI. During the period, UKA TA made a donation of £30 (2024.. £nill to the parent charity. A Jones is a Trustee of the parent charity and a partner of Thompsons Solicitors LLP. During the period, £39,909 (2024.. £nill was receivable by the group fron) Thompsons Soliciiors LLP being £27,600 (2024.. £nil} sponsorship income plus £12,30912024'. £nil) from fundraising events and donations. L Darlison is Ihe Chief Execuiive Officer of Ihe parent charity and Director of Ihe trading company. During the period. No More Mist provided repairs to the group of £52 (2024.. £nil). this entity is owned by Liz's spouse, S Darlison. In addition, L&E Electrical Contraciors provided maintenance work of £163 (2024.. £nil). in 'hIch Liz's son in law. S Lewitt, is a shareholder and director. H Childs resigned as a Trustee of the parent charity on 27 March 2024 and is a partner of Royds Withy King Solicitors. During 2024, £28,134 was receivable by the group from Ro}'ds Withy King Solicitors being £28,134 worth of sponsorship income. As H Childs resigned in the previous accounting period there are no further related party transactions to disclose. 26. CONTRIBUTIONS OF VOLUNTEERS AND SUPPORTERS The charity is grateful forthe unstinting efforts of volut]teer fundraiser5 who take part in a wide rantwe of sponsored events and other fundraising activities. The vast majority of it]come comes frojn private individuals making donations, participatii)g in Sponsored events, or leaving legacies. Page 27
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION DETAILED CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025 2025 2024 INCOME AND ENDOWMENTS Donations* grants and legacies Donations Legacies Grants Donated services and facilities 734,973 196,351 440,733 25,000 683,612 220,913 602,877 25,000 ,397,057 1,532,402 Incorne from charitable activities ADDRI income Speaker fees Events income 25,000 250 5,231 5.268 30,481 5.268 Other trading activities Trading income Events income One Lottery income Shop income 198,806 30,516 4,242 7,970 166,076 20,454 4.242 12,453 241,534 203 ?25 Investment income Deposit account interest Dividends received 37,891 5,691 21,631 4,722 43,582 26.353 Other income Rental income 4,260 4,260 Total ineoming resourees 1,716,914 1,771,508 EXPENDITURE Raising donations and legacies Wages Social security. Pensions Will w'riting Stripe and online giving fees Christmas card purchases Fundraising costs Travel expenses Charitable events Website and social media Online shop expenses UHL staff cost5 Head of nursing 120,980 9,958 9,992 3,027 15,051 1,992 29,155 182 18,152 3,301 1,699 36,407 2,48S 108,463 8,294 7,391 1,817 1,897 1,869 32,464 193 17,639 3.110 3.049 43,11 2.225 252,381 241,522 This page doe5 not fotyn part of the statutory financial ststement5 Page 28
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION DETAILED CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025 2025 2024 Other trading ¢xp¢nse$ Adininistraiion expenses 1,637 1,655 Charitable activitie5 Wages Social security PenslOIIS Provision for nursing services Nurses nieetings Website and social tnedia Patient support 5undrie5 and other support cost5 Patient travel Printiii¥ and de5i¥n magazine Project Wale5 Research centre main award Other research costs Armed Forces project expenses Infomjation expenses Patient carer day Awareness costs Travel expenses Team leaders Research grants Head of nursing Educational event expenses UHL staff costs 165,628 14,178 13,02S 635,82S 2,79S 13,201 5.79S 1.13S 4.218 140 74,312 625 171,452 15,240 11,837 649,660 5.200 12.442 5,464 1,412 2,4i8 (1,639) 578 19,611 11,482 1,253 1,671 47 84,144 108,289 40,058 6,006 6,090 44,726 2,738 9,102 1.115,319 1,156,645 Support costs Other Wages Social security Pensions Rates and water Insurance Telephone Postage and siationery Repairs aiid Tnaiiitenance Legal and professional fees GoveTnaiice Travel expenses liivestment maiiager costs TTainin¥ Sub5cripti0115 IT support and other IT cts5ts CRM expenses Carried forward 116,561 8,828 8,275 3,449 1,147 3,943 1,700 1,880 3,339 5,676 87 5,588 704 1.938 12,439 8.481 184,03S 140,589 9,613 4,709 1,032 3,905 1,674 751 6.746 4.455 513 6.022 106 4,888 10.597 7,349 213.100 This page doe5 not fotyn part of the statutory financial ststement5 Page 29
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION DETAILED ST ATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025 2025 2024 Other Brought forward Marketing and adverts Bank charges Office expenses Head of nursing Rent Depreciation of tangible fixed assets 184,035 4,859 1,265 2,077 2,48S 25,000 4,424 213,100 2,576 862 2.159 2.224 25,000 5.121 224,145 251,042 Governance cost5 Auditors, reiniineration 8,102 7,630 Total resources expended 1,601,584 1.658,494 Net ineome before gains and losses 11SJ30 113,014 Realised reeognised gains and lossts Realised gainslllosses) on fixed asset investments 3,463 60,065 Net ineome 118,793 173.079 This page doe5 not fotyn part of the statutory financial ststement5 Page 30
REGISTERED CHARITY NUMBER.. 1177039 AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 FOR MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION Mark J Rees LLP Chanered Accountants and Statutory Auditors Granville Hall Granville Road Leicester LEI 7RU
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 Page Report of the Independent Auditor5 Consolidated Statement of Financial Activities Consolidated Balance Sheet Charity Balanee Sheet Consolidated Cash Flow Statement Notes to the Consoliilated Cash Flow Statement Notes to the Consolidated Financial Statements 10 to 27 Detailed Consolidated Statement of Financial Aetivities 28 to 30
REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION Opinion We have audited the financial statements of Mesothelioma UK Charitable Incorporated Organisation (the'parent charity.) and its subsidiaries (the 'group-) for the vear ended 31 March 2025 which comprise the Consolidaied Staiement of Financial Activities, the Consolidaied Balance Sheet: the Charity Balance Sheei, the Consolidaied Cash Flow Statement and Consolidated notes to the financial statements, including a summary. of significant accounting policies. The financial reporting franiework that has been applied in their prcparation is applicable Igw and United Kingdom A¢counting Stsndards (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements.. give a trne and fair view of the state of the group's and of the parent charity's affairs as at 31 March 2025 and of its incoming resources and application of resoiirces, including its income and eXPendire, for the year then ended: have been properly prepared in accordance with United Kingdoni Generally Accepted Accounting Practice- and have been prepared in accordance with tlie requiTeinents of the Charitie5 Act 2011. Ba515 for opinion We conducted our audit in accordance with International Standards on Auditing {UK) (ISAS {UK)) and applicable law. Our respoi)sibilities ui)der those standards are I'urther described in the Auditors, resptsnsibilities for the audit of the financial Statements section of our report. We are independent of tl)e charitv in accordance with the ethical requirements tl)at are relevant to our audit of the Iinancial statementg in the UK. including the FRC'S Ethical Standard, and we have fullilled our other ethical iesponsibilities in accordai)ce with these requireinei)ts. We believe that the audit evidet)ce we have obtained is sufticient and appropriate to provide a basis for our opinion. Conclusions relating to going concern In auditing the financial siatemenis. we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have perfom)ed, we have noi identified any material uncertainties relaiing to events or conditions thaL individuallv or collectively. may casi significani doubt on Ihe group's and ihe parent charity's ability w continue as a going concern for a period of ai least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect 10 going concern are described in the relevant seciions of this report. Other information The triistccs arc responsible for the other information. The other information comprises the infomiation included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other inforniation and, except to the extent otherwise explicitly ststed in our repon, M'e do not express any forni of assurance conclusion thereon. In coiinection with our audit of the financial statements, our responsibility 15 to read the other information and, in doing so, consider whetlier the otlier infoTmation is materially incon5lStent with the finaiicial statetnents or our knowledge obtained in the audit or OtheViSe appears to be materiallj mi5Stated. If M'e identify such tnaterial ii)C0115lStencies or apparent material misstatement5, we are required to deteTmine whether this ¥iwe5 rise to a material inisstatement in the fii)ancial statements themselves. If, based oil the work we l)ave performed, we conclude that tl)ere is a material misstatement ol'this other infomiation. we are required to report that fact. We have nothing to report in this regard. Matters on whieh we are required to report by exeeption We have nothing to report in respeLt of tl)e lollowing matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report tts you if, in our opinion.. the inlonnation given in the Report of the Trustees is inconsistent in anj. material respect with the financial statements; or Ihe group has not kept adequate accounting records- Lir Ihe financial statements are not in agreemeni w'ith the accouniing records and retums: or we have nLIt received all the information and explanations we require for our audit. Page I
REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION Responsibilities of trustees As explained more fully in the Statement of Trustees, Responsibilities. the trustees are responsible for the preparation of the financial statements and for being saiisfied that theTr give a true and fair view, and for such intemal control as the Irusiees detem]ine is necessary to enable the preparatilin of financial statements thai are free from material misstaiemenL whether due to fraud or error. In preparing the fiiiancial statements, the trnstees are responsible for assessing the groups and parent charity s ability to continue as a goiiig concern, disclosing, as applicable, matters related to going conceni and using the going concern basis of accounting unless the trustees either intend to liquidate the parent or parent charity or to cease operations, or have no realistic alternative but to do so. Page 2
REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION Our responsibilities for the audit of the financial statements We have been appointed as auditors under Seciion 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulaiions made or having effect thereunder. Our objectives are to obtain reaslinable assurance about whether the financial statements as a whole are free from material misstatenient, whether due to fraud or error, and to issue a Report of the Indcpcndent Aiiditors that incliides our opinion. Reasonable assurance is g high level of assurance, but is not a guarantcc that an audit coiiducted in accordance with ISAS (UK) will always detert a material misstatenient when it exists. Misstatements can arise from fraud or error and are considered material if, individuall}. or in the aggregate. they could reasonably be experted to influence the economi¢ decisions of users taken on the basis of these financial statements. Irregularities, ii)cludingF fraud. are ii)5taiices of noii-compliance with law5 aiid rebFulations. We desiun procedures in line with our responsibilities outlined above, to detect niaterial misstatemeiits in Tespect of Iegular1tIeS, iiicluding fraud. Owing to the inherent liinitati0115 of an audit, there is an unavoidable risk that material mis5tatenients in tlie financial ststement5 may not be detected, even tl)ough the audit is properly planned and perforined in accordance with ISA'S {UK). The extent to which our procedures are eapable of deteeting irregularities, ineluding fraud, is detailed below. We obtained an understanding of the legal and regulatory Irameworks applicable to the group and the parent charity and ii)dustry in whicl) it operateg through our gei)eral commercial experience. We detemiined that the following laws and regulations were Inost signilicant." Charities SORP (FRS 102). We enquired of management conceming ihe group's and parent charity's policies and procedures relating tLI'. the identificaiion and compliance with laws and regulations. the detection and response io ihe risks of fraud. Ihe internal controls inherent within the group and parent charity to mitigate fraud risk and non-compliance to laws and regulations. We enquired of managemenL whether they were aware of any instances of non-compliance with laws and regulations or herher they had any knowledge of actual, suspected or alleged fraud. We communicated relevant laivs and regulations and potential areas of fraud to all audit team members. We remained alerr to any indications of fraud or non-compliance with laws and regulations throughout the audit. We have detennined that the principal risk areas where material irregularities coiild occur were related to posting manual journal entries to maiiipiilate financial perfonnaiice, income reco(Tnition and 5igiiificant one-off or unusual transactions. Our audit procediires were designed to respond in particular to these identified risks (including non-compliance with laws and regulations and fraud). Our audit procedures included but were not limited to.. review of a sainple of sale5 invoices and monies received from the income streams to ensure income has been accuratel), recorded aiid to cotjfirin amount5 are recobFni5ed in the correct period. A review of laws and regulations the charity is subject to. followed by compliance checks and discussion with managen)ent to ei)sure no insthnces of non-compliance. Addressing the risks of fraud through management override of controls by perfomiing a journal entry test. We did not identify any maiters during the course Lif our work that indicated non-compliance '1th laws and regulaiions or relating to fraud. Page 3
REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website ai www.frc.org.uklauditorsresponsibilities. This description forms partof our Reportof the Independent Auditors. Use of our report This report is made solelv to the charity's trustees. as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit WOTk lias been undertaken so that we might state to the charity's trustees those matters we are required to state to theni in an auditOTS' report and for no othcr purpose. To tlic fullest eytent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed. Mark J Rees LLP Chartered Accountants and Statutory Auditors Eligible to act as an auditor in teTm5 of Section 1212 of the Coinpaiiies Act 2006 Granville Hall Granville Road Leicester LEI 7RU Date.. Page 4
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025 2025 Total funds 2024 Total funds Unrestricted fund Restricted funds Notes INCOME AND ENDOWMENTS FROM Donarions, grants and legacies 879,605 517,452 lJ97,057 1,532,402 Charitable activities- primary trading income 5,481 25,000 30,481 5,268 Other trading activities Inve5tnient inconie Other income 241,534 43,582 4,260 241,534 43.582 4,260 203,225 26,353 4,260 Total ,174,462 S42,4S2 1,716,914 1,771,508 EXPF.NDITURE OIY Raising funds 242,938 11,080 254,018 243.177 Charitable activities Infonnation Expcnses A..arelless Costs Research & Audit Costs Patient Support Costs Administration and operational ¢osts 60,190 45,910 59,812 413,291 230,708 625 625 101,160 433,706 1,539 60,815 46,535 160,972 846,997 232,247 65,936 79,767 137,708 873,234 258,672 Total ,052,849 548,735 1,601,584 1,658.494 Net gains Lin investments 3,463 3,463 60,065 NET INCOME/(EXPENDITURE) 125,076 (6,283) 118,793 173,079 RECONCILIATION OF FUNDS Total funds brought fOard 925,220 358,065 1.283,285 1,110,206 TOTAL FUNDS CARRIED FORWARD 050,296 351,782 402,078 1283 285 The notes form part of these financial statements Page 5
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CONSOLIDATED BALANCE SHEET 31 MARCH 2025 2025 Total funds 2024 Total funds Unrestricted fund Restricted funds Notes FIXED ASSETS Tangible assets Investnients 10,796 800,279 10,790 800,279 12.309 791,075 811,075 811,075 803.384 CURRENT ASSETS Debtors Investments Cash at bank and in hand 19 20 168,524 168,524 229.149 100.738 359,030 251,293 351,783 603,076 419,817 351.783 771.600 688.917 CREDITORS Amounts falling due within one year 21 (180,597) (180,597) 1209.016) NET CURRENT ASSETS 239,220 591,003 479901 TOTAL ASSETS LESS CURRENT LIABILITIES 1,050,295 351,783 1,402,078 1,283,285 NET ASSETS 1050.295 351.783 1402 078 1283 285 FUNDS Unresiricted funds Restricted funds 23 1,050,295 351,783 925.220 358.065 TOTAL FUNDS 1,402 078 1283 285 The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by.. .1911112025................................. S Purves - Trustee N M8skell Trustee The notes form part of these financial statements Page 6
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CHARITY BALANCE SHEET 31 MARCH 2025 2025 Total funds 2024 Total funds Unrestricted fund Restricted funds Notes FIXED ASSETS Tangible assets Investnients 111,796 800,280 10,796 800,280 12.309 791,076 811,076 811,076 803.385 CURRENT ASSETS Debtors Investments Cash at bank and in hand 19 20 154,243 154,243 228.348 100.738 359,030 251,293 351,783 603,076 405,536 351.783 757.319 688.116 CREDITORS Amounts falling due within one year 21 (166,317) (166,317) 1208.216) NET CURRENT ASSETS 239,219 591,002 479 900 TOTAL ASSETS LESS CURRENT LIABILITIES 1,050,295 351,783 1,402,078 1,283,285 NET ASSETS 1050.295 351.783 1402 078 1283 285 FUNDS Unresiricted funds Restricted funds 23 1,050,295 351,783 925.220 358.065 TOTAL FUNDS 1,402 078 1283 285 The financial statements were approved by the Board of Trustees and authorised for issue on and M'ere signed on irs behalf by.. 1911112025................................ S Purves - Trustee N Maskell - Trustee The notes form part of these financial statements Page 7
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025 2025 ?024 Notes Cash flows from op¢rating activities Cash generated froni operations 108,378 2,655) Net cash provided byl(used in} operating activities 108,378 2.655) Cash f]ows from investing activities Purchase of tangible fixed assets Movement in fixed asset investmenis Movement in curreni assei investments Interest received (2.910) (5.742) 100,738 43.582 13,573} 2,525 26,353 Net casl) provided by investing activities 135668 Change in cash and cash equivalents in the reporting period Cash and eash equivalents at the beginning of the reporting period 244,046 22,650 359,030 336,380 Cash and cash equii'alents at the end of the reporting period 603,076 359.030 The notes form part of these financial statements Page 8
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025 RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES 2025 2024 Net income for the reporting period (as per Ihe Statement of Financial Activities) Adjustments for: Depreciation charges Gain on investTnents Interest received Decreasel{increase) in debtors (Decreasel.. increase in credito[5 118,793 173.079 4,424 (3,463} (43,582} 60,625 28,419 5,121 (60,065) (26,353} {106,757} Net Cash provided byl(used in) operations 108,378 2,655) ANALYSIS OF CHANGES IN NET FUNDS At 1.4.24 Cash flow At 31.3.25 Net cash Cash at bank and in hand 359.030 603.076 3S9 030 Liquid resources Dcposits included in ¢ash Current asset investments 100,738 100,738 100,738 100,738 Total 4$9.768 143J08 603,076 The notes form part of these financial statements Page 9
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS FOR THE YEAR ENDED 31 MARCH 2025 ACCOUNTING POLICIES Basis of pr¢paring Ihe financial s¢al¢rn¢nts The financial statements have been prepared in accordance with the Charities SORP {FRS 102)'Accounting and Reporting b}, Charities.. Siatement of Recommended Practice applicable to charities preparing their accounts in accordaiice with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021, Fiiiancial Reporting StandaTd 102'Tlie Financial Reporting Standard applicable in the UK and Republic of Ireland, and the Charities Act 2011. Mesothelioma UK CIO meets the definition of a public benefit entity under FRS 102. The financial statements have been prepared uiider tlie historical cost convention, with the exception of investments which are included at market value, as inodified by the revaluatioii of certain assets. The ¥roup financial statetnents consolidate the financial statements of Mesothelioina UK CIO aiid its subsidiary up to 31 March 2025. Reelassifieation of Prior Year Figures The presentation of certain incon)e categories has been revised in the current year io better retlect the nature of the charity's activities. Comparative figures have been reclassified accordii)gly. These changes have no impact on the nei movement in funds or the financial position reported for the prior year. Ineome All income is recognised once the Group has entitlement to the income, it is probable that the inclime will be received and the amount Lif inclime receivable can be measured reliably. For legacies, entitlement is iaken as the earlier of the date on which either.. the Group is aware of probate has been granted, the estate has been finalised and notification has been made by the execuiorfsl to the Group Ihat a distribution .111 be made, or 'hen a distribution is received from the estate. Receipt of a legacy, in whole or in parL is only considered probable when the amount can be measured reliably and the Group has been notified of the executor's intention to mgke 8 distribution. Where legacies have been notified to the Group, or the Group is aware of the graniing of probate. and the Criteria for income recognition have noi been met, then the legacy is treated as a contingent assei and disclosed if material. Doiiated Seice5 or facilities are recotwnised when tl)e Group has control over the item, any conditiot]s associated ith the dot]ated item have been met, the receipt of economic benefit froni tl)e Use of the Groiip of the time is probable and that econoinic benefit can be measured reliably. It] accordance with the Charities SORP IFRS 102), the get]eral volunteer time is not recognised and refer to the Trnstees, report for more info]n)ation about their coi)tribution. On ieLeipt, donated professional services aiid donated facilitles dre reLogni5ed on tl)t basis of the value of the ¥ift to the charity whiLh is the amount tlie Group would liave been willing to Pdy to obtain service5 or fiicilities or equivdlent ecoiioniic benefit on tlie open market; a COTrespoiidiii¥ amouiit is then recognised in expenditure in the period of receipt. Grants are included in the Con5o1idated Statement of Financidl Activitie5 on a reLeivable basis. The balaiice of income received for specific purposes but not expended during the period is shown in then relevant funds on ihe Balai)ce sheei. Where inconie is received in advance ot eniitlement of receipt, its recognition is deterred and included in crediwrs as deterred income. Where entitlement occurs before income is received, the income is accrued. Income tax recoverable in relaiion to donations received under Gift Aid or deeds of covenant is recognised at the lime of the donation. Page 10 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 ACCOUNTING POLICIES- continued Incorne- Continued Iticome tax recoverable in relation to investmenr income is recognised at the time the investment income is receivable. Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the setvice. Expenditure Expenditure is recognised once tliere is a legal or constructive obl j(Tation to transfer econoniic beiiefit to a third party, it is probable that a transfer of economic benefits Thill be required in settlemeiit and tlie aniount of the obli¥ation can be measured reliably. Expeiiditure is cla55ified by activity. The costs of each activity are made up of the totsl of direct Costs aiid Shared cost5, including 5UPPOrt Costs involved iii undertaking each activity. Direct Costs attributsble to a 5in¥le activit), are allocated directly to tliat activit),. Shared cost5 which contribute to inore than one activit), and support Costs which are not attributable to a single activitv are apportioned between those activities on a basis consigient with the use of resources. Central staff costs are allated on the basis ol'time spenL ai)d depreciation charges allocated on the portioi) of the asset's use. Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charithble activities. Support costs are those costs incurred directly in support of expendiiure on the objects of the charily and include project manageinent carried out at Headquarters. Costs of generating funds are cosis incurred in attracting voluntary, income, and Ihose incurred in Irading activities Ihat raise funds. Chariiable activities and Governance costs are cosis incurred on the charity's operations, including support costs and costs relaiing to the governance of the charity apportioned to charitable activities. Tangible fixed assets All assets costing more than £500 are capitalised. A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate Ihat the carrying value of an J. fixed asset may not be recoverable. Shonfalls between the carrying value of fixed assets and their recovergble gmounts gre recognised gs impairments. Impairment losses are recognised in the Statement of Financial Activities. Tangible fLxed assets are carried at Costs, net of depreciation and any provision for impairnient. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives. Depreciation is provided on tl)e followin¥ bases.. Fixtures and fittin¥s 15Q/o reducing balance Coniputer equipnient 33.33Q/o reducing balance Fund #ceounting General fuiid5 are unrestricted funds M'hich are available for use at the discretion of the Trustees in furtlieraiice of Ihe general objectives ol-the Group and which have not been designated tor other purposes. Restricted funds are funds which are to be used in accordance with specific restrictions imposed b}, donors or which have been raised b5, the Group for pariicular purposes. The cosis ol- raising and adininisiering such funds are charged againsi the specilic fund. The aim and use of each restricted fund is set out in the notes ihe Iinancial sthtements. Taxation The chariiy is exempt from corporation tax on lis charitable activities. Pagell continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 ACCOUNTING POLICIES- continued Pension cosls and other po$t-r¢tir¢rn¢nl b¢nefit$ The Group operates a defined coniributioii pension scheme and the pension charge represents the amounts payable by rhe Group to Ihe fund in respect of the period. Fixed a55et investments Listed investments aTe a form of financial instrument and are initially recognised at their traiisaction cost and subsequently ineasured at fair value at the Balance sheet date. Investment gains and losses, whether realised or llnreali5ed, are combined and preseiited a5 'GaIn(LOSses) on investments, in the Consolidated statement of financial activities. Investments in 5ub5idiarie5 are valued at cost less provision for impaiTment. Other investtneiits con5lSt5 of fixed teTm deposit accouiits with high street bank5 and building societies that mature more than one year froin the retx)rtin¥ date. Interest Reeeivable Interest on funds held on deposit is included when receivable and rl)e amount can be measured reliabls, bj. the Charity.: this is i)ornJally upon notification of the interest paid or payable by the institutioi) with whom the funds are deposited. Debtors Trade and other debtors are recognised at the settlement amount after any irade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. Cash at bank and in hand Cash at bank and in hand includes cash and shlin-temi highly liquid invesiments with a short maturity of Ihree months or less from the date of acquisition or opening of the deposit or similar account. Liabilities and provisions Liabilities are recognised when there is an obligation at the Balance sheei date as a resiilt of a past event, it is probable thai a transfer of economic benefit will be required in settlement, and the amount of Ihe settlement can be estiniated reliably. Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the atnount it has received as advanced paynients for the goods or services it must provide. Provisions are measured at the best estimate of the nOU11tS required to settle the obligation. Where tl)e effect of the time value of money is material, the provision is based on the present value of those nO[li)tS, discoiinted at the pre-tsx discoLllIt rate that refleLt5 the risks specific to the liability. The unwinding of thediscount is recognised in the Consolidated statement of fiiianLial activities a5 a finaiice cost. Current asset investments CUe11t asset investment5 are cash or cash equivalents with a maturity date niore thali three months after the reportiiig date but less than one year valued at cost. Going Coneern The Trustees access whether the use of going concern is appropriate i.e. whether there are anj material ui)certainries related to events or conditioi)s thai may cast significant doubt over the ability of the charit}, to coniinue as a going concern. The Trustees make this assessmeni in respect of a period of at least one year Irom Ihe date of authorisation for issue of the Iinancial staiements and have concluded thai the chariti. has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties about the charity's ability to continue as a going concern, thus they continue to adopt ihe going concem basis of accounting in preparing the financial statsments. Page 12 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY Estimates and judgements are continually evaluated and are based on historical experience and other faciors, including expectstions of future events that are believed to be reasonable under the ¢ircumsian¢es. Critical accounting e5tirnate5 and a55umption5: The Group makes estimates aiid assumptions concerning tlie ture. The resulting accounting estimates and assuniptions M'ill, by definition, seldoni equal the related actual results. The estiinates and assumptions that have a sigiiificant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. Useful economic lives of tangible assets Tlie aiinual depreciation charge for tangible fixed assets is sensitive to chan¥e5 111 the estimated useful economic lives and residual value5 of the assets. The use1 ecoiioniic lives and residual value5 are rea5se5sed aniiuallv. Tliey are ainended when nece55ary to reflect current e5timate5, based oli techiiolo¥ical advancemeiit, future investmei)ts. economic uiilisation ai)d the phjgical condition of the assets. See note 16 lor the carrying amount of the Iixture and fittings and computer equipment and note I for the useful economic lives for each class ol'assets. Residual legaeies There is some uncertainty in the value ol'residual legacies recognised due io the time lapse between when probate has been granted and the fii)al distribution is made. Donated seFviees and facilities The Group has been donated the use of the premises they operate from. The fair value of the dL)naied faciliiy has been arrived at based on the amount the Group would pay in the open market for an altemaiive. This has been calculated on an esiimaied average rate per square foot. While this is considered a reasonable reliable approach Ihere is some uncenainty due to multiple factors affecting the rental value of the property, including the size, the age and demographical area. DONATIONS, GRANTS AND LEGACIES 2025 2024 Dot]ations Legacies Grants Dot]ated services at]d facilities 734,973 196,3SI 440,733 25,OIMI 683.612 220.913 602.877 25,000 1,397,057 1,532.402 Donated services and facilities comprise of the use of the premises the Group operates from. The donation represents the deemed market rent of the propety. Page 13 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 DONATIONS, GRANTS AND LEGACIES- continued Grants received included in the above, are as follows.. 2025 2024 Amied Forces Covenant Readleys for provision of beiiefits advisor utQ Goveriimeiit Covid Medical Research B&CE Charitable Trnst for benefits advisor Meniorials Grant Sclienie to cover Me50 UK'5 AF Memorial VA T costs Grant5 for the provi5ioii of Iiursing service5 froin.. 712 6.736 133,178 9,733 15,OIMI 4.040 HASAG LASAG Readley5 Mavis Nye loundation Action on Asbestos Asbestos Action SWASAG Meso UK'S Legal Panel MAPS Benevolent fund Clydebank Asbestos Group Meso UK Legal Partner ASCE GMAVSG Grants for research projects from.. HASAG Erase-meso 87,344 57,379 22,278 22,0(Ml 150.225 22,000 19,952 44,000 48,000 11,498 31,124 25.000 24,000 39,337 25,0(H) 36,690 22,0( 5.382 5.000 37,191 36,221 440,733 602,877 OTHER TRADING ACTIVITIES 2025 2024 Trading income Events income One Lottery income Shop income 198,806 30,516 4,242 106,076 20,454 4,242 241,534 203,225 The trading income represents income from Mesothelioma UK commercial relationships which includes.. Conimission from the UK National Asbestos Re¥ister liicome raised from niembers of Mesothelioma UK Trading Ltd's legal panel: who make payment to Mesothelioma UK Trading Ltd, in retuni for the inclusion tsf tl)eir naine and logo on our w'ebsitt and legal advice leaflet. Their logo is also included oli the Mesothelioina Matters magazine, and they each have space foi one article in one of Ihe quarterly magazines per year. Page 14 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 INVESTMENT INCOME 2025 2024 Deposit accouni interest Dividends received 37,891 5,691 21,631 4.722 43,582 26.353 OTHER INCOME 2025 2024 Rental income 4,260 4,260 INCOME FROM CHARITABLE ACTIVITIES 2025 2024 ADDRI inctstne Speaker5 fees Events income 25,0(Ml Fuiids have been provided to Mesotl)elioma UK to cover the costs incurred 5UPPOrting the Au5traliaii Dust Disease Research Institute (ADDRII 10 develop resources, particularl!, specialisi mesothelioma nursiiig across Australia. RAISING FUNDS Raising donations and legaeies 2025 2024 Staff costs Will 'ritIng Stripe and online giving fees Christmas card purchases Fundraising costs Travel expenses Charitable events Wcbsite and social media Online shop expen%es UHL staff cost5 Head of nursing 140,930 3,027 124.148 1.817 11,897 1.869 32,464 193 17,639 3,110 3,049 43,111 ,992 29,155 182 18,152 3,301 1,699 36,407 252 J81 241,522 Other trading expenses 202S 2024 Administration expenses Page 15 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 CHARITABLE ACTIVITIES COSTS Direct Costs (see note l O} Support costs (see note I l) Toials Information Expenses A wareness Costs Research & Audit Costs Patient Support Costs Administration and operational costs 60,815 46,535 160,972 846,997 60,815 46,535 160,972 846,997 232,247 232,247 1,115,319 232,247 1,347,566 10. DIRECT COSTS OF CHARITABLE ACTIVITIES 2025 2024 Staff costs Provision for nursing services Nurses meetings Website and social Inedia Patient support 5undrie5 and other support cost5 Patient travel Printing and design magazine Project Wales Research centre main award Other research costs Armed Forces project expenses Infonnation expenses Patient carer da}, Awareness costs Travel expenses Team leaders Research grants Head of nursing Educational event expenses UHL staff costs 192,831 635,825 2,795 13,201 5,795 198,529 649,660 5,200 12,442 5,464 ,412 4,218 140 74,312 625 2,438 (1,639) 578 19,611 11,482 11,253 1.671 47 84,144 108.289 40,058 6,006 6,090 54,034 53,095 44,726 2,738 9,102 1,115,319 1,156,645 Page 16 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 SUPPORT COSTS Governance costs Other Totals Administration and operational costs 224,145 8,102 232,247 Support costs, included in the above, are as follows.. 2025 2024 Wages Social security Pen510115 Riltes aiid water Insurance Telephone p0sge and stationery Repairs and maintenance Legal and professional fees 116,461 8,828 8,275 3,449 1,147 3,943 1,700 1,880 3,339 140,589 10,151 9,613 4,709 1,032 3,905 1,674 751 6,746 Govemance Travel expenses Investment manager costs Training Subscriptions IT support and other IT costs CRM expeiises Marketing and adverts Bank charges Office expenses Head of nursing Rent Depreciation of tangible fixed assets Auditors, remuneration 4.455 513 6.022 106 4,888 10.597 7,349 2,576 862 2,159 2,225 25,000 5,120 7,630 87 704 1,938 12,439 8,481 4,859 ,265 2,077 2,485 25,OIHI 4,424 8,102 232,247 258,672 12. NET INCOME/{EXPENDITURE) Net incomel{expenditure) is stated after char(TjntTI(crediting)'. 2025 2024 Depreciation- owned assets 13. AUDITORS, REMUNERATION 2024 Fees pa5Jable to the charity's auditors for the audit of the charity's financial statements Page 17 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 14. TRUSTEES, REMUNERATION AND BENEFITS There M".ere no trustees, remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024. Trustees, expenses For the year ended 31 March 2025, there was £nil (2024.. £191) paid to Mr N Maskell and there was £115 (2024.. £50) paid to Ms L Creech. 15. ST AFF COSTS 2025 2024 Wage5 and salarie5 Social security Costs Other pension costs 403,169 32,964 420,504 i3,685 467,425 483,030 Remuneration of kev management personnel Ke}. tnaiia¥einent personnel are deemed to be those havin¥ authority and responsibility, dele¥ated to them by the Irusiees for planning.- directing and controlling the activities of the charity. The tothl employee benefits of the key managen)ent personnel of the charity amounted to £210,642 (2024: £112,415). The average monthly number of employees during the year was as follows.. 2025 15 2024 16 Support staff The number of employees 'hOSe emplL)yee benefits (excluding employer pension CLlSts} exceeded £60.000 was.. 2025 2024 £70,001- £80,000 Page 18 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 16. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES- 31 MARCH 2024 Unrestricted fund Restricted funds Total funds INCOME AND ENDOWMENTS FROM Donations, grants and legacies 888.469 643,933 1,532,402 Charitable activities- primary trdding income 5,268 5,268 Other trading activities Investment iiicoine Other income 203,225 26,353 203,225 26,i53 Total ,127,575 643,933 1,771,508 EXPENDITURE OIY Raising funds 243.177 243.177 Charitable activiti¢5 Iiiforniation Expenses A wareness Costs Research & Aiidit Costs Patient Support Costs Adininistration aiid operational costs 65,936 60,123 59,511 360.705 258.672 65,936 79,767 137,708 873,234 258 672 19,644 78,197 512,529 Total 1,048,124 610,370 1,658,494 Net gains Lin investmenis 60.065 60,065 NET INCOME 139,516 33,563 173,079 RECOP4CILIATION OF FUP4DS Total funds brought forward 785.704 324.502 1,110,206 TOTAL FUNDS CARRIED FORWARD 925 220 358 065 1,283 285 Page 19 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 17. TAf44GIBLE FIXED ASSETS- GROUP Fixtures and fittings Computer equipment Totals At l April 2024 Additions 3,787 33,5S4 2,910 37,341 2,910 At 31 March 2025 3,787 36,464 40,251 DEPRECIATION Ai l April 2024 Charge for year 22,087 4,297 25,032 4,423 126 At 31 MarLh 2025 NET BOOK VALUE At 31 March 2025 716 10,080 At 31 March 2024 842 TANGIBLE FIXED ASSETS- CHARITY Fixtures and fittings Computer equipment Totals COST At l April 2024 Additions 3,787 33,554 2,910 37,341 2,910 At 31 March 2025 3.787 36,464 40,251 DEPRECIATION At l April 2024 Charge for year 2,945 126 22,087 25,032 At 31 March 2025 NET BOOK VALUE At 31 Marcli 2025 716 10,080 At 31 March 2024 842 Page 20 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 18. FIXED ASSET INVESTMENTS-GROUP 2025 2024 Shares Other 544,641 255,638 791,075 800,279 791.075 Additional infom)ation as follows.. Cash and settlenients peiiding Listed investments Totals MARKET VALUE At l April 2024 Additions Disp05a15 Revaluations 774,647 91,771 (337,378) 3,463 16,428 343,069 (347,359) 791,07S 434,840 (684,737) 3,463 At 31 March 2025 $32,503 12,138 $44,641 NET BOOK VALUE At 31 March 2025 532,503 12,138 544,641 At 31 March 2024 774,647 16,428 791,075 FIXED ASSET INVESTMENTS- CHARITY 2025 2024 Shares Other S44,642 255,638 791.076 800,280 791,076 Additional infotynation a5 follows.. Shares iii group undertakings Cash and settlenients pendin¥ Listed investTneiits Totals MARKET VALUE At l April 2024 Addiiions Disposals Revaluations 774,647 91,771 (337,378) 16,428 343,069 (347,359) 791,076 434,840 (684,737) At 31 March 2025 532 503 544 642 NET BOOK VALUE At 31 Marcli 2025 532,503 544,642 At 31 March 2024 791076 Page21 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 FIXED ASSET INVESTMENTS- CHARITY- continued Cost or valuation at 31 March 2025 is represented by.. Shares in group undertaking5 Cash and settlements pending Lisl¢d inve5tment5 Totals Valuation in 2025 Cost 532,503 532,503 12,139 12,138 532,503 12,138 544,642 The charity's investments at the balance sheet date in the share capital of companies include the following.. Mesotheliorna UK Trading Liniited Registered office.. 235 Lou¥hborough Road, MouiitsotTel, Lou¥hborou¥h, LE12 7AS Company number.. 12541690 Nature of busines5.' Sponsorship and advert15in¥ sales Class of share= Ordinary holdiiig 2025 2024 Aggregate capital and reserves Profit for the year 197,169 164,421 FIXED ASSET INVESTMENTS-GROUP AND CHARITY Investments (neither listed nor unlisted) were as follows.. 2025 2024 Bank deposits 255,638 Other investments consist5 of fixed tem) deposit account5 Wlth high street banks and building societie5 which mature iii Inore than a year. There were no investJneiit assets outside the UK. 19. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR- GROUP 2025 2024 Trade debtors Other debtors Prepayments and accrued income 28.431 10.449 129,644 14,599 5,817 208,7i3 168 $24 229 149 Page 22 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 19. DEBTORS: AMOUNTS FALLING DUE WITHIiN ONE YEAR- CHARITY 2025 2024 Trade debiors Amounts owed by group undertakings Other debtors Prepa)'Tnents and accrued income 10,168 3,982 10,449 129,644 13,798 5,817 208,733 154,243 228,348 20. CURRENT ASSET INVESTMENTS- GROVP AND CHARITY 202S 2024 Bank deposlts 100.738 CuTrent asset investments consists of fixed rate dep051ts M'ith hi¥h Street banks ai)d buildii)g societies that mature niore than 3 tnonths after the reporting date but less than 12 months. 21. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR- GROUP 2025 2024 Trade crediiors Social security and other taxes Other creditors Accruals and deferred income 84,241 17,758 4,676 73,922 65,983 14,376 4,954 123 703 180 S97 209016 CREDITORS: AMOUNTS FALLING DUE WITHJN ONE YEAR- CHARITY 2025 2024 Trade crediiors Amounts owed to group undertakings Social security. and other iaxes Other creditors Accruals and deferred income 84,241 65,983 10.105 9,318 4,676 68,082 4,954 117.863 166 208,216 Within accruals and deferred income are funds received in advance from fundraising challenges vet IL) take place at the year end. The deferred income is £16,163 (2024.. £11.097). The events are expected to take place in ?025126. 22. LEASING AGREEMENTS-GROUP AND CHARITY Minimum lease payments under non-cancellable operating legses fall due as follows.. 2025 2024 Within one year Be.e¢n one and five years In more than five year5 25,1100 loo,0 25,000 i (10,000 162,093 187,093 Page 23 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 23. MOVEMENT IN FUNDS Net nJoi'¢m¢nt in funds At 31.3.25 Al 1.4.24 Unrestricted fund5 General fund 925,220 125,075 ,050,295 Restricted funds Graiits and donation5 for nurses Project Nl Grants aiid donati0115 for research Grants aiid donation5 for other restricted projects Project Wale5 Mick May Meinorial Fund Commonwealth Mesothelioma Research Network 31,881 39,074 149,183 16,277 48,1S8 39,074 (94,119) 8,653 19,801 109,473 12,624 (8,246) 52,599 21,277 11,5S5 162,072 358 06S 82 341783 TOTAL FUNDS ,283,285 118,793 ,402,078 Net movement in funds, included in the above are as follows.. Incomi1)¥ resources Resource5 expended Gai115 and 105se5 Movetnent in funds Unrestricted funds General fund 1,172,825 {1,051,213) 3,463 125,075 Restrieted funds Granis and doi)ations for nurses Grants and donations for research Granis and donations for other restricted projecis Project Wales Mick May Memorial Fund Commonwealth Mesothelioma Research Network 418,834 7,041 (402,557) (101,160) 16,277 (94,119) 37.968 1.010 52,599 (2S,344) (9.256) 12,624 (8,246) 52,599 25,000 10,417) 14,583 542.452 548.734 6.282 TOTAL FUNDS ,718277 ,599 947) 118793 Page 24 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 23. MOVEMENT IN FUNDS- continued Comparatives for movement in funds Net movement in ndS At 31.3.24 At 1.4.23 Unrestricted fund5 General fund 785,704 139,516 925,220 Restricted funds Grants aiid donati0115 for nurse5 Arined Forces Graiit Project Nl Grants aiid donat10115 for research Grants ai)d donations for other restricted projects Project Wales Mick May Memorial Fund 141,276 1,474 35,714 1109,395) (1,474) 3.360 149,183 31,881 39,074 149,183 24,826 11,739 109473 (16,173) 8,062 8,653 19,801 10947J 324 502 358 065 TOTAL FUNDS 1,110,206 173,079 1,283,285 Comparative net tnovement in funds, included in the above are as follow5.. Incoming resources ResouTce5 expended Gain5 and losses Movetnent in fui)ds Unrestricted funds General fund 1.125,921 {1.046,470) 60,065 li9,516 Restricted funds Granis and donations for nurses Armed Forces Grant Project Nl Granis and donations for research Granis and donations for other restricted projecis Project Wales Cost-Benefit study 385.747 712 3,360 206,590 1495.142) (2,186) 1109.395) (1,474) 3,360 149.183 (57.407) 17,023 10,500 20,000 (33,196) (2,438) 20,000) (16,173) 8,062 643,932 610,369 33,563 TOTAL FUNDS 1769 85i 1.656 839) 173 079 Unrestricted funds are available to be spent for any purposes of the charity. Page 25 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 23. MOVEMENT IN FUNDS- continued Purposes of restricted funds Grants and donations for nurses Variou5 grants and donations were received during the year towards the cost of the Mesothelioma UK clinical nurse specialists and teain leaders. Project Nl These are ring-fenced donations restricted for Mesothelioma UK to establish or expand services across Northern Ireland. Mesothelioma UK clinical nurse specialists have been recruited for Northern Ireland who l[l lead the development of appropriate 5ervice5. Project Wales Tliese are riiig-fenced donati0115 restricted for Mesothelioma UK to establish or expand services across Wales. Mesothelionia UK clinical nurse specialists have been recruited in tlie region who will lead the development of appropriaie services. Miek May Memorial Fund Most ol'ihe funds in the MMMF were a grant from the Schroder Foundation. This is for use under the'lmproving Outcomes and Experience, pillar, to ensure patients have equitable access to the best treatmenL care, infomation ai)d support including helping to build a comprehensive mulii-disciplinary team approach and evidenced based care paihways and guidelines which are fundamental to achieving improved outcomes and experiences. Commonwealth Mesothelioma Researeh Network Mesothelioma UK are supporting the Australian Dust Disease Research Instituie (ADDRI) to develop resources, particularly specialist mesothelioma nursing. across Australia. In addition the two organisations have established an international research network and togeiher they plan io develop a menu of resources and ei'ents to help share mesothelioma specific learning, expertise and knowledge across all countries in the commonwealth. Grants for R¢5¢8rch Donations were received restricted for both general research and specific research projects. Grant5 for other restricted projects Other donatioiis M'ere received and restricted for the education of tl)e t]urse5, tom'ards the ndIng of Me50thelioma UK benefits advisors, towards the funding of support groups and to help towards tTavel costs. 24. EMPLOYEE BENEFIT OBLIGATIONS Tlie charity operates a defined LOTltribution pension scheme. Tlie a55ets of the scheine art Iield separiltely from those uf the Group iii an iiidependtntlv administered fund. The pension c05t Lharge5 represent the LOTitributions paydble by the charity to the fund in the Jear Lind iimount to £31,292 (2024.. £28,841). At tlie balance sheet date £4,0 {2024.. £3,620} were payable ts) the fund and are iiicluded in Lreditors. Page 26 continued...
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION NOTES TO THE CONSOLIDATED FINANCIAL STA TEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025 24. CONTINGENT ASSET The Group has been notified of an entitlement to legacies of which the Group is unable to measure reliably the value of amounts due and therefore no provision has been made in the accounts. 25. RELATED PARTY DISCLOSURES A L Coates is a TNstee of the parent charity and a partneT of Irwin Mitchell Solicitors. Duriiig the period, £64,059 (2024.. £36.828) was receivable by the gTOUP from Irwin Mitchell Solicitor5 being £27,600 (2024.. £24,000) sponsorship income plus £36,459 (2024.. £1 ?,8281 from ndraISing events and donations. Also. during the peTlOd, the group acquired will writing and other professional services from Irwin Mitchell Solicitors at a cost of £2,204 (2024.. £1,547). D McKinley was a Trustee of the parent charit),: resi¥nin¥ on 31 Decetllber 2024, and Senior Executive Officer of the British Thoracic Oiicology Group IBTOG}. Duriiig the period, BTOG paid rent to the parent charity of £4,260 {2024.. £4,260} aiid received aniount5 for recharged expe115es of £36012024.. £194). C Evans is a frustee of the parent charity and Chief Operating Officer at UK Asbestos Training Association Ltd (UKATAI. During the period, UKA TA made a donation of £30 (2024.. £nill to the parent charity. A Jones is a Trustee of the parent charity and a partner of Thompsons Solicitors LLP. During the period, £39,909 (2024.. £nill was receivable by the group fron) Thompsons Soliciiors LLP being £27,600 (2024.. £nil} sponsorship income plus £12,30912024'. £nil) from fundraising events and donations. L Darlison is Ihe Chief Execuiive Officer of Ihe parent charity and Director of Ihe trading company. During the period. No More Mist provided repairs to the group of £52 (2024.. £nil). this entity is owned by Liz's spouse, S Darlison. In addition, L&E Electrical Contraciors provided maintenance work of £163 (2024.. £nil). in 'hIch Liz's son in law. S Lewitt, is a shareholder and director. H Childs resigned as a Trustee of the parent charity on 27 March 2024 and is a partner of Royds Withy King Solicitors. During 2024, £28,134 was receivable by the group from Ro}'ds Withy King Solicitors being £28,134 worth of sponsorship income. As H Childs resigned in the previous accounting period there are no further related party transactions to disclose. 26. CONTRIBUTIONS OF VOLUNTEERS AND SUPPORTERS The charity is grateful forthe unstinting efforts of volut]teer fundraiser5 who take part in a wide rantwe of sponsored events and other fundraising activities. The vast majority of it]come comes frojn private individuals making donations, participatii)g in Sponsored events, or leaving legacies. Page 27
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION DETAILED CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025 2025 2024 INCOME AND ENDOWMENTS Donations* grants and legacies Donations Legacies Grants Donated services and facilities 734,973 196,351 440,733 25,000 683,612 220,913 602,877 25,000 ,397,057 1,532,402 Incorne from charitable activities ADDRI income Speaker fees Events income 25,000 250 5,231 5.268 30,481 5.268 Other trading activities Trading income Events income One Lottery income Shop income 198,806 30,516 4,242 7,970 166,076 20,454 4.242 12,453 241,534 203 ?25 Investment income Deposit account interest Dividends received 37,891 5,691 21,631 4,722 43,582 26.353 Other income Rental income 4,260 4,260 Total ineoming resourees 1,716,914 1,771,508 EXPENDITURE Raising donations and legacies Wages Social security. Pensions Will w'riting Stripe and online giving fees Christmas card purchases Fundraising costs Travel expenses Charitable events Website and social media Online shop expenses UHL staff cost5 Head of nursing 120,980 9,958 9,992 3,027 15,051 1,992 29,155 182 18,152 3,301 1,699 36,407 2,48S 108,463 8,294 7,391 1,817 1,897 1,869 32,464 193 17,639 3.110 3.049 43,11 2.225 252,381 241,522 This page doe5 not fotyn part of the statutory financial ststement5 Page 28
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION DETAILED CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025 2025 2024 Other trading ¢xp¢nse$ Adininistraiion expenses 1,637 1,655 Charitable activitie5 Wages Social security PenslOIIS Provision for nursing services Nurses nieetings Website and social tnedia Patient support 5undrie5 and other support cost5 Patient travel Printiii¥ and de5i¥n magazine Project Wale5 Research centre main award Other research costs Armed Forces project expenses Infomjation expenses Patient carer day Awareness costs Travel expenses Team leaders Research grants Head of nursing Educational event expenses UHL staff costs 165,628 14,178 13,02S 635,82S 2,79S 13,201 5.79S 1.13S 4.218 140 74,312 625 171,452 15,240 11,837 649,660 5.200 12.442 5,464 1,412 2,4i8 (1,639) 578 19,611 11,482 1,253 1,671 47 84,144 108,289 40,058 6,006 6,090 44,726 2,738 9,102 1.115,319 1,156,645 Support costs Other Wages Social security Pensions Rates and water Insurance Telephone Postage and siationery Repairs aiid Tnaiiitenance Legal and professional fees GoveTnaiice Travel expenses liivestment maiiager costs TTainin¥ Sub5cripti0115 IT support and other IT cts5ts CRM expenses Carried forward 116,561 8,828 8,275 3,449 1,147 3,943 1,700 1,880 3,339 5,676 87 5,588 704 1.938 12,439 8.481 184,03S 140,589 9,613 4,709 1,032 3,905 1,674 751 6.746 4.455 513 6.022 106 4,888 10.597 7,349 213.100 This page doe5 not fotyn part of the statutory financial ststement5 Page 29
MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANJSATION DETAILED ST ATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025 2025 2024 Other Brought forward Marketing and adverts Bank charges Office expenses Head of nursing Rent Depreciation of tangible fixed assets 184,035 4,859 1,265 2,077 2,48S 25,000 4,424 213,100 2,576 862 2.159 2.224 25,000 5.121 224,145 251,042 Governance cost5 Auditors, reiniineration 8,102 7,630 Total resources expended 1,601,584 1.658,494 Net ineome before gains and losses 11SJ30 113,014 Realised reeognised gains and lossts Realised gainslllosses) on fixed asset investments 3,463 60,065 Net ineome 118,793 173.079 This page doe5 not fotyn part of the statutory financial ststement5 Page 30